Contact
Merck KGaA, Darmstadt, Germany
Investor Relations
Frankfurter Strasse 250
64293 Darmstadt
Germany
Phone: +49 6151 72 3321
e-mail: investor.relations@merckgroup.com
www.merckgroup.com

WKN:	659990
ISIN:	DE0006599905
Ticker Symbol:	MRK

Financial Statements Q1 2023 – Q4 2024

Content

Net sales/Net sales growth by business sector Merck KGaA, Darmstadt, Germany

€ million	2023 Q1	2023 Q2	2023 H1	2023 Q3	2023 9M	2023 Q4	2023 H2	2023 FY	2024 Q1	2024 Q2	2024 H1	2024 Q3	2024 9M	2024 Q4	2024 H2	2024 FY
Group	**5,293.0**	**5,302.4**	**10,595.3**	**5,173.1**	**15,768.4**	**5,224.5**	**10,397.6**	**20,992.9**	**5,119.8**	**5,352.2**	**10,472.0**	**5,266.1**	**15,738.0**	**5,417.7**	**10,683.8**	**21,155.8**
YoY Δ	95.2	-266.0	-170.8	-632.7	-803.5	-435.9	-1,068.5	-1,239.3	-173.2	49.8	-123.4	93.0	-30.4	193.2	286.2	162.8
Acquisitions Δ	9.4	3.2	12.6	3.1	15.6	3.4	6.4	19.0	-0.6	-2.2	-2.7	-1.9	-4.6	20.0	18.1	15.3
Fx Δ	43.5	-207.4	-163.9	-395.5	-559.4	-342.4	-737.9	-901.8	-108.3	-38.4	-146.7	-102.6	-249.3	-27.6	-130.2	-277.0
Organic Δ	42.3	-61.8	-19.5	-240.2	-259.7	-96.9	-337.1	-356.6	-64.3	90.4	26.1	197.5	223.6	200.9	398.4	424.5
Life Science	**2,486.8**	**2,353.5**	**4,840.3**	**2,190.9**	**7,031.2**	**2,249.4**	**4,440.2**	**9,280.5**	**2,143.7**	**2,258.1**	**4,401.8**	**2,209.7**	**6,611.5**	**2,304.5**	**4,514.2**	**8,916.0**
YoY Δ	41.4	-294.2	-252.9	-489.9	-742.7	-357.1	-846.9	-1,099.8	-343.1	-95.5	-438.5	18.8	-419.7	55.2	74.0	-364.5
Acquisitions Δ	6.3	-0.2	6.0	0.1	6.2	0.1	0.2	6.3	0.0	0.0	0.0	0.0	0.0	6.7	6.7	6.7
Fx Δ	20.9	-64.6	-43.7	-135.7	-179.4	-105.3	-240.9	-284.6	-30.4	-8.5	-38.9	-27.2	-66.1	4.8	-22.5	-61.3
Organic Δ	14.2	-229.4	-215.2	-354.3	-569.6	-251.9	-606.2	-821.5	-312.7	-87.0	-399.7	46.1	-353.6	43.7	89.8	-309.9
Healthcare	**1,905.5**	**2,049.5**	**3,955.0**	**2,066.3**	**6,021.3**	**2,031.9**	**4,098.2**	**8,053.2**	**2,047.7**	**2,136.7**	**4,184.4**	**2,133.4**	**6,317.8**	**2,136.7**	**4,270.1**	**8,454.5**
YoY Δ	110.5	125.3	235.9	-23.0	212.8	1.6	-21.4	214.5	142.2	87.2	229.4	67.1	296.5	104.8	171.9	401.3
Acquisitions Δ	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fx Δ	14.8	-104.6	-89.8	-178.1	-267.9	-185.7	-363.8	-453.6	-49.3	-21.8	-71.2	-62.0	-133.2	-31.1	-93.1	-164.3
Organic Δ	95.7	229.9	325.7	155.1	480.8	187.3	342.4	668.1	191.5	109.1	300.6	129.1	429.7	135.9	265.0	565.6
Electronics	**900.7**	**899.3**	**1,800.0**	**915.9**	**2,715.9**	**943.2**	**1,859.1**	**3,659.2**	**928.4**	**957.4**	**1,885.8**	**923.0**	**2,808.8**	**976.5**	**1,899.5**	**3,785.3**
YoY Δ	-56.7	-97.1	-153.8	-119.8	-273.6	-80.4	-200.2	-354.0	27.7	58.1	85.8	7.1	92.8	33.3	40.3	126.1
Acquisitions Δ	3.1	3.4	6.5	2.9	9.5	3.3	6.2	12.8	-0.6	-2.2	-2.7	-1.9	-4.6	13.3	11.4	8.6
Fx Δ	7.7	-38.2	-30.4	-81.7	-112.1	-51.4	-133.2	-163.6	-28.6	-8.1	-36.7	-13.4	-50.1	-1.3	-14.7	-51.3
Organic Δ	-67.6	-62.3	-129.9	-41.0	-170.9	-32.3	-73.3	-203.2	56.8	68.3	125.2	22.3	147.5	21.3	43.6	168.8

	2023 Q1	2023 Q2	2023 H1	2023 Q3	2023 9M	2023 Q4	2023 H2	2023 FY	2024 Q1	2024 Q2	2024 H1	2024 Q3	2024 9M	2024 Q4	2024 H2	2024 FY
Group																
YoY %	1.8%	-4.8%	-1.6%	-10.9%	-4.8%	-7.7%	-9.3%	-5.6%	-3.3%	0.9%	-1.2%	1.8%	-0.2%	3.7%	2.8%	0.8%
Acquisitions %	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	0.2%	0.1%
Fx %	0.8%	-3.7%	-1.5%	-6.8%	-3.4%	-6.0%	-6.4%	-4.1%	-2.0%	-0.7%	-1.4%	-2.0%	-1.6%	-0.5%	-1.3%	-1.3%
Organic %	0.8%	-1.1%	-0.2%	-4.1%	-1.6%	-1.7%	-2.9%	-1.6%	-1.2%	1.7%	0.2%	3.8%	1.4%	3.8%	3.8%	2.0%
Life Science																
YoY %	1.7%	-11.1%	-5.0%	-18.3%	-9.6%	-13.7%	-16.0%	-10.6%	-13.8%	-4.1%	-9.1%	0.9%	-6.0%	2.5%	1.7%	-3.9%
Acquisitions %	0.3%	0.0%	0.1%	0.0%	0.1%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	0.2%	0.1%
Fx %	0.9%	-2.4%	-0.9%	-5.1%	-2.3%	-4.0%	-4.6%	-2.7%	-1.2%	-0.4%	-0.8%	-1.2%	-0.9%	0.2%	-0.5%	-0.7%
Organic %	0.6%	-8.7%	-4.2%	-13.2%	-7.3%	-9.7%	-11.5%	-7.9%	-12.6%	-3.7%	-8.3%	2.1%	-5.0%	1.9%	2.0%	-3.3%
Healthcare																
YoY %	6.2%	6.5%	6.3%	-1.1%	3.7%	0.1%	-0.5%	2.7%	7.5%	4.3%	5.8%	3.2%	4.9%	5.2%	4.2%	5.0%
Acquisitions %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Fx %	0.8%	-5.4%	-2.4%	-8.5%	-4.6%	-9.1%	-8.8%	-5.8%	-2.6%	-1.1%	-1.8%	-3.0%	-2.2%	-1.5%	-2.3%	-2.0%
Organic %	5.3%	11.9%	8.8%	7.4%	8.3%	9.2%	8.3%	8.5%	10.1%	5.3%	7.6%	6.2%	7.1%	6.7%	6.5%	7.0%
Electronics																
YoY %	-5.9%	-9.7%	-7.9%	-11.6%	-9.2%	-7.9%	-9.7%	-8.8%	3.1%	6.5%	4.8%	0.8%	3.4%	3.5%	2.2%	3.4%
Acquisitions %	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	-0.1%	-0.2%	-0.2%	-0.2%	-0.2%	1.4%	0.6%	0.2%
Fx %	0.8%	-3.8%	-1.6%	-7.9%	-3.8%	-5.0%	-6.5%	-4.1%	-3.2%	-0.9%	-2.0%	-1.5%	-1.8%	-0.1%	-0.8%	-1.4%
Organic %	-7.1%	-6.3%	-6.7%	-4.0%	-5.7%	-3.2%	-3.6%	-5.1%	6.3%	7.6%	7.0%	2.4%	5.4%	2.3%	2.3%	4.6%

EBITDA pre by business sector Merck KGaA, Darmstadt, Germany

€ million	2023 Q1	2023 Q2	2023 H1	2023 Q3	2023 9M	2023 Q4	2023 H2	2023 FY	2024 Q1	2024 Q2	2024 H1	2024 Q3	2024 9M	2024 Q4	2024 H2	2024 FY
Group	**1,587.0**	**1,553.3**	**3,140.3**	**1,445.6**	**4,585.9**	**1,293.0**	**2,738.7**	**5,878.9**	**1,453.9**	**1,508.9**	**2,962.8**	**1,617.7**	**4,580.6**	**1,491.1**	**3,108.8**	**6,071.6**
% Margin	30.0%	29.3%	29.6%	27.9%	29.1%	24.7%	26.3%	28.0%	28.4%	28.2%	28.3%	30.7%	29.1%	27.5%	29.1%	28.7%
YoY Δ	-41.8	-228.7	-270.5	-364.8	-635.3	-334.9	-699.7	-970.2	-133.1	-44.3	-177.4	172.1	-5.4	198.0	370.1	192.7
Acquisitions Δ	-6.1	-3.0	-9.1	-5.7	-14.9	-5.0	-10.7	-19.9	0.0	-0.1	-0.1	-0.2	-0.3	-2.8	-2.9	-3.0
Fx Δ	-7.7	-101.2	-108.9	-120.1	-229.0	-106.4	-226.5	-335.4	-50.7	-32.0	-82.8	-71.8	-154.6	-54.3	-126.1	-208.9
Organic Δ	-27.9	-124.6	-152.5	-239.0	-391.5	-223.5	-462.5	-615.0	-82.4	-12.2	-94.6	244.1	149.5	255.1	499.2	404.6
Life Science	**900.6**	**711.9**	**1,612.5**	**615.1**	**2,227.6**	**592.0**	**1,207.1**	**2,819.6**	**611.2**	**654.7**	**1,265.9**	**646.4**	**1,912.4**	**676.8**	**1,323.3**	**2,589.2**
% Margin	36.2%	30.2%	33.3%	28.1%	31.7%	26.3%	27.2%	30.4%	28.5%	29.0%	28.8%	29.3%	28.9%	29.4%	29.3%	29.0%
YoY Δ	-26.5	-293.8	-320.3	-361.3	-681.6	-258.3	-619.6	-939.9	-289.4	-57.2	-346.6	31.3	-315.3	84.8	116.1	-230.5
Acquisitions Δ	-4.3	1.6	-2.7	-7.0	-9.8	-1.4	-8.5	-11.2	0.0	0.0	0.0	0.0	0.0	-5.2	-5.2	-5.2
Fx Δ	-9.4	-32.8	-42.2	-46.6	-88.8	-35.6	-82.3	-124.4	-16.6	-13.6	-30.2	-12.1	-42.4	-4.8	-16.9	-47.1
Organic Δ	-12.8	-262.6	-275.4	-307.6	-583.0	-221.3	-528.9	-804.3	-272.8	-43.6	-316.4	43.4	-272.9	94.8	138.2	-178.1
Healthcare	**589.6**	**703.6**	**1,293.2**	**685.4**	**1,978.5**	**564.5**	**1,249.9**	**2,543.1**	**708.0**	**719.8**	**1,427.8**	**835.7**	**2,263.5**	**731.2**	**1,566.9**	**2,994.6**
% Margin	30.9%	34.3%	32.7%	33.2%	32.9%	27.8%	30.5%	31.6%	34.6%	33.7%	34.1%	39.2%	35.8%	34.2%	36.7%	35.4%
YoY Δ	60.5	100.0	160.5	-25.5	135.0	-68.5	-94.0	66.5	118.4	16.2	134.6	150.3	284.9	166.7	317.0	451.6
Acquisitions Δ	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fx Δ	4.9	-83.8	-78.8	-148.0	-226.8	-129.0	-277.0	-355.8	-48.6	-16.4	-65.0	-34.8	-99.8	-26.4	-61.1	-126.1
Organic Δ	55.6	183.8	239.3	122.5	361.8	60.5	183.0	422.3	167.0	32.6	199.6	185.1	384.7	193.0	378.1	577.7
Electronics	**237.3**	**261.7**	**499.1**	**207.9**	**707.0**	**206.0**	**413.9**	**913.0**	**236.6**	**255.3**	**491.9**	**235.2**	**727.1**	**242.5**	**477.7**	**969.6**
% Margin	26.4%	29.1%	27.7%	22.7%	26.0%	21.8%	22.3%	25.0%	25.5%	26.7%	26.1%	25.5%	25.9%	24.8%	25.2%	25.6%
YoY Δ	-52.0	-31.3	-83.3	-93.7	-177.1	-102.2	-195.9	-279.2	-0.7	-6.5	-7.2	27.4	20.2	36.5	63.8	56.6
Acquisitions Δ	-1.3	-1.6	-2.9	-2.1	-5.0	-3.2	-5.4	-8.3	0.0	-0.1	-0.1	-0.2	-0.3	2.5	2.4	2.3
Fx Δ	6.6	-14.5	-7.9	-37.9	-45.8	-20.9	-58.8	-66.7	-10.0	1.7	-8.3	-3.6	-11.9	3.1	-0.5	-8.8
Organic Δ	-57.3	-15.3	-72.5	-53.6	-126.2	-78.0	-131.7	-204.2	9.3	-8.1	1.2	31.1	32.3	30.8	61.9	63.1
Corporate/Others	**-140.5**	**-123.9**	**-264.5**	**-62.7**	**-327.2**	**-69.5**	**-132.3**	**-396.7**	**-101.9**	**-120.8**	**-222.8**	**-99.6**	**-322.4**	**-159.4**	**-259.1**	**-481.8**
YoY Δ	-23.7	-3.6	-27.3	115.6	88.3	94.1	209.8	182.4	38.6	3.1	41.7	-36.9	4.8	-89.9	-126.8	-85.1

€ million	2023 Q1	2023 Q2	2023 H1	2023 Q3	2023 9M	2023 Q4	2023 H2	2023 FY	2024 Q1	2024 Q2	2024 H1	2024 Q3	2024 9M	2024 Q4	2024 H2	2024 FY
Group																
YoY %	-2.6%	-12.8%	-7.9%	-20.2%	-12.2%	-20.6%	-20.3%	-14.2%	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%
Acquisitions %	-0.4%	-0.2%	-0.3%	-0.3%	-0.3%	-0.3%	-0.3%	-0.3%	0.0%	0.0%	0.0%	0.0%	0.0%	-0.2%	-0.1%	-0.1%
Fx %	-0.5%	-5.7%	-3.2%	-6.6%	-4.4%	-6.5%	-6.6%	-4.9%	-3.2%	-2.1%	-2.6%	-5.0%	-3.4%	-4.2%	-4.6%	-3.6%
Organic %	-1.7%	-7.0%	-4.5%	-13.2%	-7.5%	-13.7%	-13.5%	-9.0%	-5.2%	-0.8%	-3.0%	16.9%	3.3%	19.7%	18.2%	6.9%
Life Science																
YoY %	-2.9%	-29.2%	-16.6%	-37.0%	-23.4%	-30.4%	-33.9%	-25.0%	-32.1%	-8.0%	-21.5%	5.1%	-14.2%	14.3%	9.6%	-8.2%
Acquisitions %	-0.5%	0.2%	-0.1%	-0.7%	-0.3%	-0.2%	-0.5%	-0.3%	0.0%	0.0%	0.0%	0.0%	0.0%	-0.9%	-0.4%	-0.2%
Fx %	-1.0%	-3.3%	-2.2%	-4.8%	-3.1%	-4.2%	-4.5%	-3.3%	-1.8%	-1.9%	-1.9%	-2.0%	-1.9%	-0.8%	-1.4%	-1.7%
Organic %	-1.4%	-26.1%	-14.2%	-31.5%	-20.0%	-26.0%	-29.0%	-21.4%	-30.3%	-6.1%	-19.6%	7.1%	-12.3%	16.0%	11.4%	-6.3%
Healthcare																
YoY %	11.4%	16.6%	14.2%	-3.6%	7.3%	-10.8%	-7.0%	2.7%	20.1%	2.3%	10.4%	21.9%	14.4%	29.5%	25.4%	17.8%
Acquisitions %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Fx %	0.9%	-13.9%	-7.0%	-20.8%	-12.3%	-20.4%	-20.6%	-14.4%	-8.2%	-2.3%	-5.0%	-5.1%	-5.0%	-4.7%	-4.9%	-5.0%
Organic %	10.5%	30.4%	21.1%	17.2%	19.6%	9.6%	13.6%	17.1%	28.3%	4.6%	15.4%	27.0%	19.4%	34.2%	30.3%	22.7%
Electronics																
YoY %	-18.0%	-10.7%	-14.3%	-31.1%	-20.0%	-33.1%	-32.1%	-23.4%	-0.3%	-2.5%	-1.4%	13.2%	2.9%	17.7%	15.4%	6.2%
Acquisitions %	-0.4%	-0.5%	-0.5%	-0.7%	-0.6%	-1.1%	-0.9%	-0.7%	0.0%	0.0%	0.0%	-0.1%	0.0%	1.2%	0.6%	0.2%
Fx %	2.3%	-4.9%	-1.4%	-12.6%	-5.2%	-6.8%	-9.6%	-5.6%	-4.2%	0.7%	-1.7%	-1.7%	-1.7%	1.5%	-0.1%	-1.0%
Organic %	-19.8%	-5.2%	-12.5%	-17.8%	-14.3%	-25.3%	-21.6%	-17.1%	3.9%	-3.1%	0.2%	15.0%	4.6%	14.9%	15.0%	6.9%
Corporate/Others																
YoY %	20.3%	3.0%	11.5%	-64.8%	-21.3%	-57.5%	-61.3%	-31.5%	-27.5%	-2.5%	-15.8%	58.8%	-1.5%	129.3%	95.9%	21.4%

Due to rounding the sum of individual values may not add up to totals presented.

Income Statement Merck KGaA, Darmstadt, Germany

Group	2023								2024								Change YoY							
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	**5,293.0**	**5,302.4**	**10,595.3**	**5,173.1**	**15,768.4**	**5,224.5**	**10,397.6**	**20,992.9**	**5,119.8**	**5,352.2**	**10,472.0**	**5,266.1**	**15,738.0**	**5,417.7**	**10,683.8**	**21,155.8**	-3.3%	0.9%	-1.2%	1.8%	-0.2%	3.7%	2.8%	0.8%
Cost of sales	-1,972.5	-2,138.9	-4,111.4	-2,161.8	-6,273.2	-2,327.3	-4,489.1	-8,600.5	-2,110.6	-2,119.2	-4,229.8	-2,122.0	-6,351.8	-2,319.3	-4,441.3	-8,671.1	7.0%	-0.9%	2.9%	-1.8%	1.3%	-0.3%	-1.1%	0.8%
thereof amortization of intangible assets	-48.2	-46.2	-94.3	-40.3	-134.7	-38.6	-78.9	-173.2	-38.2	-33.1	-71.3	-28.5	-99.8	-31.4	-60.0	-131.3	-20.6%	-28.4%	-24.4%	-29.3%	-25.9%	-18.5%	-24.0%	-24.2%
Gross profit	3,320.4	3,163.5	6,483.9	3,011.3	9,495.2	2,897.2	5,908.5	12,392.4	3,009.2	3,233.0	6,242.1	3,144.0	9,386.2	3,098.4	6,242.5	12,484.6	-9.4%	2.2%	-3.7%	4.4%	-1.1%	6.9%	5.7%	0.7%
in % of net sales	*62.7%*	*59.7%*	*61.2%*	*58.2%*	*60.2%*	*55.5%*	*56.8%*	*59.0%*	*58.8%*	*60.4%*	*59.6%*	*59.7%*	*59.6%*	*57.2%*	*58.4%*	*59.0%*								
SG&A	-1,688.2	-1,593.6	-3,281.8	-1,447.0	-4,728.8	-1,609.3	-3,056.3	-6,338.1	-1,497.3	-1,793.3	-3,290.6	-1,523.2	-4,813.8	-1,746.8	-3,270.0	-6,560.6	-11.3%	12.5%	0.3%	5.3%	1.8%	8.5%	7.0%	3.5%
in % of net sales	*31.9%*	*30.1%*	*31.0%*	*28.0%*	*30.0%*	*30.8%*	*29.4%*	*30.2%*	*29.2%*	*33.5%*	*31.4%*	*28.9%*	*30.6%*	*32.2%*	*30.6%*	*31.0%*								
Marketing and selling expenses	-1,109.1	-1,139.4	-2,248.5	-1,104.3	-3,352.9	-1,157.5	-2,261.8	-4,510.4	-1,087.1	-1,145.9	-2,233.0	-1,100.8	-3,333.7	-1,202.6	-2,303.4	-4,536.4	-2.0%	0.6%	-0.7%	-0.3%	-0.6%	3.9%	1.8%	0.6%
thereof amortization of intangible assets (M&S)	-151.3	-148.9	-300.2	-146.7	-446.9	-149.3	-296.0	-596.2	-144.7	-145.3	-290.0	-137.0	-427.0	-140.6	-277.6	-567.6	-4.3%	-2.4%	-3.4%	-6.7%	-4.5%	-5.8%	-6.2%	-4.8%
Administration expenses	-357.9	-345.0	-702.9	-312.0	-1,014.9	-377.4	-689.4	-1,392.3	-331.7	-336.1	-667.8	-309.1	-977.0	-392.6	-701.7	-1,369.6	-7.3%	-2.6%	-5.0%	-0.9%	-3.7%	4.0%	1.8%	-1.6%
Impairment losses and reversals (IFRS 9)	-2.2	-9.7	-11.9	-28.3	-40.2	-10.3	-38.6	-50.5	1.0	0.1	1.1	-2.3	-1.2	-7.2	-9.5	-8.4	n.m.	n.m.	n.m.	-92.0%	-97.1%	-29.8%	-75.5%	-83.4%
Other operating expenses/income	-219.0	-99.4	-318.4	-2.3	-320.8	-64.1	-66.5	-384.9	-79.5	-311.4	-390.8	-111.1	-501.9	-144.3	-255.4	-646.2	-63.7%	213.2%	22.7%	>1.000%	56.5%	125.1%	284.3%	67.9%
Impairments**	-9.7	-36.9	-46.6	-3.8	-50.4	-36.9	-40.7	-87.2	-0.5	-222.2	-222.7	-1.9	-224.6	-52.8	-54.7	-277.4	-95.1%	502.8%	378.1%	-50.4%	345.8%	43.3%	34.5%	217.9%
Research and development costs	-597.3	-600.4	-1,197.7	-581.1	-1,778.8	-666.5	-1,247.5	-2,445.2	-580.6	-647.4	-1,227.9	-523.7	-1,751.6	-527.5	-1,051.2	-2,279.1	-2.8%	7.8%	2.5%	-9.9%	-1.5%	-20.9%	-15.7%	-6.8%
in % of net sales	*11.3%*	*11.3%*	*11.3%*	*11.2%*	*11.3%*	*12.8%*	*12.0%*	*11.6%*	*11.3%*	*12.1%*	*11.7%*	*9.9%*	*11.1%*	*9.7%*	*9.8%*	*10.8%*								
thereof amortization of intangible assets (R&D)	-4.4	-3.0	-7.4	-3.2	-10.6	-3.4	-6.5	-14.0	-3.3	-3.3	-6.6	-3.3	-9.9	-5.6	-8.9	-15.5	-25.6%	9.8%	-11.2%	4.1%	-6.6%	67.6%	36.8%	11.2%
EBIT	**1,035.0**	**969.5**	**2,004.4**	**983.2**	**2,987.7**	**621.5**	**1,604.7**	**3,609.1**	**931.3**	**792.3**	**1,723.6**	**1,097.1**	**2,820.7**	**824.2**	**1,921.3**	**3,644.9**	-10.0%	-18.3%	-14.0%	11.6%	-5.6%	32.6%	19.7%	1.0%
in % of net sales	*19.6%*	*18.3%*	*18.9%*	*19.0%*	*18.9%*	*11.9%*	*15.4%*	*17.2%*	*18.2%*	*14.8%*	*16.5%*	*20.8%*	*17.9%*	*15.2%*	*18.0%*	*17.2%*								
Depreciation and amortization	455.5	482.3	937.8	435.2	1,373.0	506.7	941.9	1,879.7	453.5	680.1	1,133.6	449.3	1,582.9	550.8	1,000.1	2,133.8	-0.4%	41.0%	20.9%	3.2%	15.3%	8.7%	6.2%	13.5%
EBITDA	**1,490.5**	**1,451.8**	**2,942.3**	**1,418.4**	**4,360.7**	**1,128.2**	**2,546.6**	**5,488.9**	**1,384.8**	**1,472.5**	**2,857.3**	**1,546.4**	**4,403.7**	**1,375.0**	**2,921.4**	**5,778.7**	-7.1%	1.4%	-2.9%	9.0%	1.0%	21.9%	14.7%	5.3%
in % of net sales	*28.2%*	*27.4%*	*27.8%*	*27.4%*	*27.7%*	*21.6%*	*24.5%*	*26.1%*	*27.0%*	*27.5%*	*27.3%*	*29.4%*	*28.0%*	*25.4%*	*27.3%*	*27.3%*								
EBITDA pre	**1,587.0**	**1,553.3**	**3,140.3**	**1,445.6**	**4,585.9**	**1,293.0**	**2,738.7**	**5,878.9**	**1,453.9**	**1,508.9**	**2,962.8**	**1,617.7**	**4,580.6**	**1,491.1**	**3,108.8**	**6,071.6**	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%
in % of net sales	*30.0%*	*29.3%*	*29.6%*	*27.9%*	*29.1%*	*24.7%*	*26.3%*	*28.0%*	*28.4%*	*28.2%*	*28.3%*	*30.7%*	*29.1%*	*27.5%*	*29.1%*	*28.7%*								
Financial result	-22.7	-75.7	-98.4	-46.0	-144.3	19.1	-26.8	-125.2	-32.2	-7.2	-39.4	-54.1	-93.5	-15.0	-69.1	-108.5	42.1%	-90.6%	-60.0%	17.7%	-35.2%	n.m.	157.6%	-13.4%
Profit before income tax from continuing operations	1,012.3	893.8	1,906.1	937.3	2,843.3	640.6	1,577.9	3,483.9	899.1	785.2	1,684.3	1,043.0	2,727.3	809.2	1,852.2	3,536.5	-11.2%	-12.1%	-11.6%	11.3%	-4.1%	26.3%	17.4%	1.5%
Income tax	-212.6	-187.7	-400.3	-196.8	-597.1	-53.0	-249.8	-650.1	-199.6	-179.8	-379.4	-231.3	-610.7	-139.9	-371.2	-750.6	-6.1%	-4.2%	-5.2%	17.5%	2.3%	163.8%	48.6%	15.5%
Income tax rate	*21.0%*	*21.0%*	*21.0%*	*21.0%*	*21.0%*	*8.3%*	*15.8%*	*18.7%*	*22.2%*	*22.9%*	*22.5%*	*22.2%*	*22.4%*	*17.3%*	*20.0%*	*21.2%*								
Profit after tax from continuing operations	799.7	706.1	1,505.8	740.4	2,246.2	587.6	1,328.0	2,833.8	699.5	605.4	1,304.9	811.7	2,116.5	669.3	1,480.9	2,785.8	-12.5%	-14.3%	-13.3%	9.6%	-5.8%	13.9%	11.5%	-1.7%
Profit after tax from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Profit after tax	799.7	706.1	1,505.8	740.4	2,246.2	587.6	1,328.0	2,833.8	699.5	605.4	1,304.9	811.7	2,116.5	669.3	1,480.9	2,785.8	-12.5%	-14.3%	-13.3%	9.6%	-5.8%	13.9%	11.5%	-1.7%
of which: attributable to Merck KGaA shareholders (	**796.2**	**703.6**	**1,499.8**	**738.7**	**2,238.4**	**585.3**	**1,323.9**	**2,823.7**	**694.2**	**607.4**	**1,301.6**	**808.8**	**2,110.4**	**666.2**	**1,475.0**	**2,776.6**	-12.8%	-13.7%	-13.2%	9.5%	-5.7%	13.8%	11.4%	-1.7%
of which: attributable to non-controlling interests	**3.5**	**2.5**	**6.0**	**1.8**	**7.8**	**2.3**	**4.1**	**10.1**	**5.2**	**-2.0**	**3.3**	**2.9**	**6.1**	**3.1**	**5.9**	**9.2**	48.4%	n.m.	-45.8%	61.2%	-21.4%	33.1%	45.4%	-9.0%
EPS in €	**1.83**	**1.62**	**3.45**	**1.70**	**5.15**	**1.35**	**3.05**	**6.49**	**1.60**	**1.40**	**2.99**	**1.86**	**4.85**	**1.53**	**3.39**	**6.39**	-12.6%	-13.6%	-13.3%	9.4%	-5.8%	13.3%	11.1%	-1.5%
thereof from continuing operations	1.83	1.62	3.45	1.70	5.15	1.35	3.05	6.49	1.60	1.40	2.99	1.86	4.85	1.53	3.39	6.39	-12.6%	-13.6%	-13.3%	9.4%	-5.8%	13.3%	11.1%	-1.5%
thereof from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EPS pre in €*	**2.36**	**2.20**	**4.57**	**2.07**	**6.64**	**1.85**	**3.92**	**8.49**	**2.06**	**2.20**	**4.26**	**2.30**	**6.56**	**2.07**	**4.37**	**8.63**	-12.7%	0.0%	-6.8%	11.1%	-1.2%	11.9%	11.5%	1.6%
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8								
Reconciliation to EBITDA pre																								
EBITDA	1,490.5	1,451.8	2,942.3	1,418.4	4,360.7	1,128.2	2,546.6	5,488.9	1,384.8	1,472.5	2,857.3	1546.4	4,403.7	1,375.0	2,921.4	5,778.7	-7.1%	1.4%	-2.9%	9.0%	1.0%	21.9%	14.7%	5.3%
Adjustments																								
thereof: Cost of Sales	2.7	4.6	7.2	10.4	17.6	24.9	35.3	42.6	4.1	5.3	9.4	2.1	11.5	29.4	31.5	40.9	53.8%	16.6%	30.3%	-80.1%	-34.8%	18.0%	-10.9%	-3.9%
thereof: Marketing and selling expenses	-0.9	5.4	4.5	8.0	12.4	31.9	39.9	44.3	9.1	2.5	11.6	-1.2	10.4	20.1	18.9	30.4	n.m.	-54.1%	157.6%	n.m.	-16.8%	-37.0%	-52.6%	-31.3%
thereof: Administration expenses	71.7	41.9	113.6	33.9	147.5	98.3	132.2	245.8	43.0	29.8	72.8	30.9	103.7	50.0	80.9	153.7	-40.0%	-28.9%	-35.9%	-8.8%	-29.7%	-49.1%	-38.8%	-37.5%
thereof: Other operating expenses/income	30.9	42.1	73.0	-25.5	47.5	2.9	-22.6	50.5	7.5	-6.1	1.5	36.8	38.3	19.0	55.8	57.3	-75.7%	n.m.	-98.0%	n.m.	-19.4%	546.1%	n.m.	13.6%
thereof: Research and development	-7.9	7.6	-0.3	0.5	0.1	6.8	7.2	6.9	5.4	4.9	10.3	2.7	13.0	-2.5	0.2	10.5	n.m.	-35.0%	n.m.	489.9%	>1.000%	n.m.	-96.6%	52.5%
Total	**96.5**	**101.5**	**198.0**	**27.2**	**225.2**	**164.9**	**192.1**	**390.1**	**69.1**	**36.5**	**105.5**	**71.4**	**176.9**	**116.0**	**187.4**	**292.9**	-28.4%	-64.1%	-46.7%	162.0%	-21.5%	-29.6%	-2.4%	-24.9%
EBITDA pre	**1,587.0**	**1,553.3**	**3,140.3**	**1,445.6**	**4,585.9**	**1,293.0**	**2,738.7**	**5,878.9**	**1,453.9**	**1,508.9**	**2,962.8**	**1617.7**	**4,580.6**	**1,491.1**	**3,108.8**	**6,071.6**	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%

Due to rounding the sum of individual values may not add up to totals presented.
* For continuing operations.
** Only reflects impairments classified as adjustments.

Reconciliation to EBITDA, EBITDA pre and EPS pre

Group	2023								2024								Change YoY							
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
a) Reconciliation to EBITDA and EBITDA pre																								
EBITDA																								
EBIT	1,035.0	969.5	2,004.4	983.2	2,987.7	621.5	1,604.7	3,609.1	931.3	792.3	1,723.6	1,097.1	2,820.7	824.2	1,921.3	3,644.9	-10.0%	-18.3%	-14.0%	11.6%	-5.6%	32.6%	19.7%	1.0%
Depreciation and amortization	455.5	482.3	937.8	435.2	1,373.0	506.7	941.9	1,879.7	453.5	680.1	1,133.6	449.3	1,582.9	550.8	1,000.1	2,133.8	-0.4%	41.0%	20.9%	3.2%	15.3%	8.7%	6.2%	13.5%
Regular depreciation and amortization*	242.0	243.2	485.2	241.1	726.3	266.9	508.0	993.2	257.6	265.6	523.2	269.8	793.1	298.6	568.5	1,091.7	6.5%	9.2%	7.8%	11.9%	9.2%	11.9%	11.9%	9.9%
Impairments not adjusted	0.0	4.2	4.2	0.0	4.2	11.8	11.8	16.0	9.2	10.6	19.8	8.7	28.6	21.7	30.5	50.3	>1.000%	153.4%	371.8%	>1.000%	579.7%	84.5%	158.7%	214.8%
Amortization of purchased intangible assets	203.8	198.1	401.9	190.3	592.2	191.2	381.5	783.3	186.2	181.7	367.9	168.8	536.7	177.6	346.5	714.4	-8.6%	-8.3%	-8.5%	-11.3%	-9.4%	-7.1%	-9.2%	-8.8%
Impairments (net)**	9.7	36.9	46.6	3.8	50.4	36.9	40.7	87.2	0.5	222.2	222.7	1.9	224.6	52.8	54.7	277.4	-95.1%	502.8%	378.1%	-50.4%	345.8%	43.3%	34.5%	217.9%
Total	**1,490.5**	**1,451.8**	**2,942.3**	**1,418.4**	**4,360.7**	**1,128.2**	**2,546.6**	**5,488.9**	**1,384.8**	**1,472.5**	**2,857.3**	**1,546.4**	**4,403.7**	**1,375.0**	**2,921.4**	**5,778.7**	-7.1%	1.4%	-2.9%	9.0%	1.0%	21.9%	14.7%	5.3%
Adjustments																								
Acquisition costs	9.2	4.8	14.0	3.7	17.7	0.8	4.4	18.5	2.5	0.4	2.9	5.5	8.4	17.2	22.7	25.6	-72.7%	-92.4%	-79.4%	51.6%	-52.3%	>1.000%	411.0%	38.7%
Restructuring costs	44.3	39.3	83.6	24.6	108.2	140.3	164.9	248.5	44.6	34.1	78.7	37.2	115.9	27.6	64.8	143.5	0.7%	-13.3%	-5.9%	51.4%	7.1%	-80.3%	-60.7%	-42.3%
Integration costs/IT costs	23.5	27.1	50.6	28.8	79.4	39.0	67.8	118.4	17.4	21.2	38.6	21.7	60.2	42.4	64.1	102.7	-26.1%	-21.7%	-23.7%	-24.8%	-24.1%	8.9%	-5.4%	-13.3%
Gain (-)/ losses (+) on the divestment of businesses	0.3	17.1	17.4	-48.8	-31.4	-20.1	-68.8	-51.4	-4.8	-51.7	-56.5	0.3	-56.2	9.7	10.0	-46.5	n.m.	n.m.	n.m.	n.m.	79.1%	n.m.	n.m.	-9.6%
Other one-time costs	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7	67.6	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Total	**96.5**	**101.5**	**198.0**	**27.2**	**225.2**	**164.9**	**192.1**	**390.1**	**69.1**	**36.5**	**105.5**	**71.4**	**176.9**	**116.0**	**187.4**	**292.9**	-28.4%	-64.1%	-46.7%	162.0%	-21.5%	-29.6%	-2.4%	-24.9%
EBITDA pre	**1,587.0**	**1,553.3**	**3,140.3**	**1,445.6**	**4,585.9**	**1,293.0**	**2,738.7**	**5,878.9**	**1,453.9**	**1,508.9**	**2,962.8**	**1,617.7**	**4,580.6**	**1,491.1**	**3,108.8**	**6,071.6**	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%
b) Reconciliation to EPS pre																								
1) Reconciliation starting from EBITDA pre																								
EBITDA pre	1,587.0	1,553.3	3,140.3	1,445.6	4,585.9	1,293.0	2,738.7	5,878.9	1,453.9	1,508.9	2,962.8	1,617.7	4,580.6	1,491.1	3,108.8	6,071.6	-8.4%	-2.9%	-5.7%	11.9%	-0.1%	15.3%	13.5%	3.3%
Regular depreciation and amortization*	-242.0	-243.2	-485.2	-241.1	-726.3	-266.9	-508.0	-993.2	-257.6	-265.6	-523.2	-269.8	-793.1	-298.6	-568.5	-1,091.7	6.5%	9.2%	7.8%	11.9%	9.2%	11.9%	11.9%	9.9%
Impairments not adjusted	0.0	-4.2	-4.2	0.0	-4.2	-11.8	-11.8	-16.0	-9.2	-10.6	-19.8	-8.7	-28.6	-21.7	-30.5	-50.3	>1.000%	153.4%	371.8%	>1.000%	579.7%	84.5%	158.7%	214.8%
Financial result	-22.7	-75.7	-98.4	-46.0	-144.3	19.1	-26.8	-125.2	-32.2	-7.2	-39.4	-54.1	-93.5	-15.0	-69.1	-108.5	42.1%	-90.6%	-60.0%	17.7%	-35.2%	n.m.	157.6%	-13.4%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								
Profit before income tax pre	1,322.3	1,230.2	2,552.5	1,158.5	3,711.1	1,033.5	2,192.1	4,744.6	1,154.8	1,225.5	2,380.4	1,285.1	3,665.4	1,155.7	2,440.7	4,821.1	-12.7%	-0.4%	-6.7%	10.9%	-1.2%	11.8%	11.3%	1.6%
Income tax pre	-290.9	-270.6	-561.6	-254.9	-816.4	-227.4	-482.3	-1,043.8	-254.1	-269.6	-523.7	-282.7	-806.4	-254.3	-537.0	-1,060.6	-12.7%	-0.4%	-6.7%	10.9%	-1.2%	11.8%	11.3%	1.6%
underlying tax rate	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*								
Non-controlling interest	-3.5	-2.5	-6.0	-1.8	-7.8	-2.3	-4.1	-10.1	-5.2	2.0	-3.3	-2.9	-6.1	-3.1	-5.9	-9.2	48.4%	n.m.	-45.8%	61.2%	-21.4%	33.1%	45.4%	-9.0%
Net income pre	1,027.9	957.1	1,984.9	901.9	2,886.8	803.9	1,705.7	3,690.7	895.6	957.9	1,853.4	999.5	2,852.9	898.4	1,897.8	3,751.3	-12.9%	0.1%	-6.6%	10.8%	-1.2%	11.8%	11.3%	1.6%
EPS pre in €* **	**2.36**	**2.20**	**4.57**	**2.07**	**6.64**	**1.85**	**3.92**	**8.49**	**2.06**	**2.20**	**4.26**	**2.30**	**6.56**	**2.07**	**4.37**	**8.63**	-12.7%	0.0%	-6.8%	11.1%	-1.2%	11.9%	11.5%	1.6%
2) Reconciliation starting from Profit before tax																								
Profit before income tax	1,012.3	893.8	1,906.1	937.3	2,843.3	640.6	1,577.9	3,483.9	899.1	785.2	1,684.3	1,043.0	2,727.3	809.2	1,852.2	3,536.5	-11.2%	-12.1%	-11.6%	11.3%	-4.1%	26.3%	17.4%	1.5%
Amortization of purchased intangible assets	203.8	198.1	401.9	190.3	592.2	191.2	381.5	783.3	186.2	181.7	367.9	168.8	536.7	177.6	346.5	714.4	-8.6%	-8.3%	-8.5%	-11.3%	-9.4%	-7.1%	-9.2%	-8.8%
Impairments**	9.7	36.9	46.6	3.8	50.4	36.9	40.7	87.2	0.5	222.2	222.7	1.9	224.6	52.8	54.7	277.4	-95.1%	502.8%	378.1%	-50.4%	345.8%	43.3%	34.5%	217.9%
Adjustments																								
Acquisition costs	9.2	4.8	14.0	3.7	17.7	0.8	4.4	18.5	2.5	0.4	2.9	5.5	8.4	17.2	22.7	25.6	-72.7%	-92.4%	-79.4%	51.6%	-52.3%	>1.000%	411.0%	38.7%
Restructuring costs	44.3	39.3	83.6	24.6	108.2	140.3	164.9	248.5	44.6	34.1	78.7	37.2	115.9	27.6	64.8	143.5	0.7%	-13.3%	-5.9%	51.4%	7.1%	-80.3%	-60.7%	-42.3%
Integration costs/IT costs	23.5	27.1	50.6	28.8	79.4	39.0	67.8	118.4	17.4	21.2	38.6	21.7	60.2	42.4	64.1	102.7	-26.1%	-21.7%	-23.7%	-24.8%	-24.1%	8.9%	-5.4%	-13.3%
Gain (-)/ losses (+) on the divestment of businesses	0.3	17.1	17.4	-48.8	-31.4	-20.1	-68.8	-51.4	-4.8	-51.7	-56.5	0.3	-56.2	9.7	10.0	-46.5	n.m.	n.m.	n.m.	n.m.	79.1%	n.m.	n.m.	-9.6%
Other one-time costs	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7	67.6	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Adjustments within Financial result	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0								
Total adjustments	96.5	101.5	198.0	27.2	225.2	164.9	192.1	390.1	69.1	36.5	105.5	71.4	176.9	116.0	187.4	292.9	-28.4%	-64.1%	-46.7%	162.0%	-21.5%	-29.6%	-2.4%	-24.9%
Profit before income tax pre	1,322.3	1,230.2	2,552.5	1,158.5	3,711.1	1,033.5	2,192.1	4,744.6	1,154.8	1,225.5	2,380.4	1,285.1	3,665.4	1,155.7	2,440.7	4,821.1	-12.7%	-0.4%	-6.7%	10.9%	-1.2%	11.8%	11.3%	1.6%
Income tax pre	-290.9	-270.6	-561.6	-254.9	-816.4	-227.4	-482.3	-1,043.8	-254.1	-269.6	-523.7	-282.7	-806.4	-254.3	-537.0	-1,060.6	-12.7%	-0.4%	-6.7%	10.9%	-1.2%	11.8%	11.3%	1.6%
underlying tax rate	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*	*22.0%*								
Total costs excluded from Net income	**231.7**	**253.5**	**485.2**	**163.2**	**648.4**	**218.6**	**381.8**	**867.0**	**201.3**	**350.5**	**551.8**	**190.7**	**742.5**	**232.2**	**422.8**	**974.7**	-13.1%	38.3%	13.7%	16.8%	14.5%	6.2%	10.7%	12.4%
Total costs excluded from EPS in €	0.53	0.58	1.12	0.38	1.49	0.50	0.88	1.99	0.46	0.81	1.27	0.44	1.71	0.53	0.97	2.24	-13.2%	39.7%	13.4%	15.8%	14.8%	6.0%	10.2%	12.6%
Non-controlling interest	-3.5	-2.5	-6.0	-1.8	-7.8	-2.3	-4.1	-10.1	-5.2	2.0	-3.3	-2.9	-6.1	-3.1	-5.9	-9.2	48.4%	n.m.	-45.8%	61.2%	-21.4%	33.1%	45.4%	-9.0%
Net income pre	1,027.9	957.1	1,984.9	901.9	2,886.8	803.9	1,705.7	3,690.7	895.6	957.9	1,853.4	999.5	2,852.9	898.4	1,897.8	3,751.3	-12.9%	0.1%	-6.6%	10.8%	-1.2%	11.8%	11.3%	1.6%
EPS pre in €* **	**2.36**	**2.20**	**4.57**	**2.07**	**6.64**	**1.85**	**3.92**	**8.49**	**2.06**	**2.20**	**4.26**	**2.30**	**6.56**	**2.07**	**4.37**	**8.63**	-12.7%	0.0%	-6.8%	11.1%	-1.2%	11.9%	11.5%	1.6%
Number of theoretical shares in million	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8	434.8								

Due to rounding the sum of individual values may not add up to totals presented.
* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.
** Only reflects impairments classified as adjustments.
*** For continuing operations.

Breakdown of depreciation and amortization and adjustments

Group € million	Division	2023 Q1	2023 Q2	2023 H1	2023 Q3	2023 9M	2023 Q4	2023 H2	2023 FY	2024 Q1	2024 Q2	2024 H1	2024 Q3	2024 9M	2024 Q4	2024 H2	2024 FY	Change YoY Q1	Change YoY Q2	Change YoY H1	Change YoY Q3	Change YoY 9M	Change YoY Q4	Change YoY H2	Change YoY FY
a) Depreciation and amortization																									
Regular depreciation and amortization*	**all**	**242.0**	**243.2**	**485.2**	**241.1**	**726.3**	**266.9**	**508.0**	**993.2**	**257.6**	**265.6**	**523.2**	**269.8**	**793.1**	**298.6**	**568.5**	**1,091.7**	6.5%	9.2%	7.8%	11.9%	9.2%	11.9%	11.9%	9.9%
Impairments not adjusted	**all**	**0.0**	**4.2**	**4.2**	**0.0**	**4.2**	**11.8**	**11.8**	**16.0**	**9.2**	**10.6**	**19.8**	**8.7**	**28.6**	**21.7**	**30.5**	**50.3**	>1.000%	153.4%	371.8%	>1.000%	579.7%	84.5%	158.7%	214.8%
Amortization of purchased intangible assets																									
Life Science	LS	118.2	115.8	234.0	108.5	342.5	108.8	217.3	451.3	107.8	108.4	216.3	99.7	316.0	109.2	208.9	425.1	-8.7%	-6.4%	-7.6%	-8.1%	-7.7%	0.4%	-3.9%	-5.8%
Healthcare	HC	1.5	1.6	3.2	1.7	4.8	1.7	3.3	6.5	1.6	1.6	3.2	1.6	4.8	1.5	3.1	6.4	3.7%	-0.9%	1.3%	-4.1%	-0.6%	-7.1%	-5.6%	-2.2%
Electronics	EL	84.1	80.6	164.7	80.1	244.8	80.8	160.8	325.6	76.8	71.7	148.4	67.5	215.9	66.9	134.5	282.9	-8.7%	-11.1%	-9.9%	-15.7%	-11.8%	-17.1%	-16.4%	-13.1%
Total		**203.8**	**198.1**	**401.9**	**190.3**	**592.2**	**191.2**	**381.5**	**783.3**	**186.2**	**181.7**	**367.9**	**168.8**	**536.7**	**177.6**	**346.5**	**714.4**	-8.6%	-8.3%	-8.5%	-11.3%	-9.4%	-7.1%	-9.2%	-8.8%
Impairments (net)**	**all**	9.7	36.9	46.6	3.8	50.4	36.9	40.7	**87.2**	0.5	222.2	222.7	1.9	224.6	52.8	54.7	**277.4**	-95.1%	502.8%	378.1%	-50.4%	345.8%	43.3%	34.5%	217.9%
Total depreciation and amortization		**455.5**	**482.3**	**937.8**	**435.2**	**1,373.0**	**506.7**	**941.9**	**1,879.7**	**453.5**	**680.1**	**1,133.6**	**449.3**	**1,582.9**	**550.8**	**1,000.1**	**2,133.8**	-0.4%	41.0%	20.9%	3.2%	15.3%	8.7%	6.2%	13.5%
b) Adjustments																									
Acquisition costs		**9.2**	**4.8**	**14.0**	**3.7**	**17.7**	**0.8**	**4.4**	**18.5**	**2.5**	**0.4**	**2.9**	**5.5**	**8.4**	**17.2**	**22.7**	**25.6**	-72.7%	-92.4%	-79.4%	51.6%	-52.3%	>1.000%	411.0%	38.7%
Restructuring costs																									
Life Science	LS	0.4	1.8	2.2	4.3	6.5	23.1	27.4	29.6	18.0	8.6	26.6	14.3	40.9	32.4	46.7	73.4	>1.000%	365.9%	>1.000%	235.3%	528.1%	40.2%	70.6%	147.5%
Healthcare	HC	-7.3	12.0	4.7	2.6	7.3	24.2	26.8	31.6	5.3	2.3	7.6	3.1	10.7	-2.6	0.5	8.1	n.m.	-81.2%	60.9%	19.5%	46.2%	n.m.	-98.1%	-74.4%
Electronics	EL	2.2	6.9	9.1	9.9	18.9	41.0	50.9	60.0	4.1	4.2	8.3	7.8	16.1	5.9	13.7	22.0	88.8%	-39.4%	-8.9%	-20.7%	-15.1%	-85.6%	-73.0%	-63.3%
Corporate and Other	CO	49.0	18.5	67.6	7.9	75.4	52.0	59.8	127.4	17.2	19.1	36.3	12.0	48.2	-8.1	3.8	40.1	-65.0%	2.9%	-46.4%	52.3%	-36.1%	n.m.	-93.6%	-68.5%
Total		**44.3**	**39.3**	**83.6**	**24.6**	**108.2**	**140.3**	**164.9**	**248.5**	**44.6**	**34.1**	**78.7**	**37.2**	**115.9**	**27.6**	**64.8**	**143.5**	0.7%	-13.3%	-5.9%	51.4%	7.1%	-80.3%	-60.7%	-42.3%
Integration costs/IT costs																									
Integration Cost	LS/EL/CO	1.9	2.0	4.0	2.2	6.1	1.4	3.5	7.5	2.3	2.1	4.4	-1.0	3.4	8.0	7.0	11.4	18.4%	4.0%	11.0%	n.m.	-44.2%	481.4%	97.2%	51.6%
ERP/HR systems	all	21.6	25.0	46.6	26.7	73.2	37.6	64.3	110.9	15.1	19.1	34.2	22.7	56.8	34.5	57.1	91.3	-30.1%	-23.8%	-26.7%	-15.0%	-22.4%	-8.3%	-11.1%	-17.6%
Total		**23.5**	**27.1**	**50.6**	**28.8**	**79.4**	**39.0**	**67.8**	**118.4**	**17.4**	**21.2**	**38.6**	**21.7**	**60.2**	**42.4**	**64.1**	**102.7**	-26.1%	-21.7%	-23.7%	-24.8%	-24.1%	8.9%	-5.4%	-13.3%
Gain (-)/ losses (+) on the divestment of businesses																									
Costs related to former business activities	CO	0.0	21.0	21.0	-3.0	18.0	-16.6	-19.6	1.4	0.0	-18.6	-18.6	0.0	-18.6	0.0	0.0	-18.6	n.m.	n.m.	n.m.	-100.0%	n.m.	-100.0%	-100.0%	n.m.
Costs related to former business activities	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.4	0.0	1.4	15.2	15.2	16.5	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Sale of CH, Allergopharma and others	HC	0.3	-3.9	-3.6	-45.8	-49.4	-3.4	-49.2	-52.8	-4.8	-34.5	-39.3	0.0	-39.3	-5.9	-5.9	-45.2	n.m.	786.9%	>1.000%	n.m.	-20.4%	72.0%	-88.0%	-14.4%
Costs related to former business activities	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5	0.8	0.8	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total		**0.3**	**17.1**	**17.4**	**-48.8**	**-31.4**	**-20.1**	**-68.8**	**-51.4**	**-4.8**	**-51.7**	**-56.5**	**0.3**	**-56.2**	**9.7**	**10.0**	**-46.5**	n.m.	n.m.	n.m.	n.m.	79.1%	n.m.	n.m.	-9.6%
Other one-time costs																									
Others	HC	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
	LS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
	EL	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
	CO	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7	67.6	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Total		**19.2**	**13.2**	**32.4**	**18.9**	**51.3**	**4.8**	**23.7**	**56.1**	**9.4**	**32.5**	**41.9**	**6.6**	**48.5**	**19.1**	**25.7**	**67.6**	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Total adjustments		**96.5**	**101.5**	**198.0**	**27.2**	**225.2**	**164.9**	**192.1**	**390.1**	**69.1**	**36.5**	**105.5**	**71.4**	**176.9**	**116.0**	**187.4**	**292.9**	-28.4%	-64.1%	-46.7%	162.0%	-21.5%	-29.6%	-2.4%	-24.9%

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Life Science	2023								2024								Change YoY							
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	**2,486.8**	**2,353.5**	**4,840.3**	**2,190.9**	**7,031.2**	**2,249.4**	**4,440.2**	**9,280.5**	**2,143.7**	**2,258.1**	**4,401.8**	**2,209.7**	**6,611.5**	**2,304.5**	**4,514.2**	**8,916.0**	-13.8%	-4.1%	-9.1%	0.9%	-6.0%	2.5%	1.7%	-3.9%
Cost of sales	-999.2	-1,078.2	-2,077.5	-1,031.1	-3,108.6	-1,127.6	-2,158.8	-4,236.3	-987.6	-1,041.9	-2,029.5	-1,008.2	-3,037.6	-1,112.4	-2,120.6	-4,150.1	-1.2%	-3.4%	-2.3%	-2.2%	-2.3%	-1.3%	-1.8%	-2.0%
thereof amortization of intangible assets	-13.3	-13.5	-26.8	-8.3	-35.1	-7.2	-15.4	-42.2	-7.1	-6.9	-14.0	-5.5	-19.5	-11.7	-17.2	-31.2	-46.7%	-48.8%	-47.8%	-33.3%	-44.3%	62.9%	11.4%	-26.1%
Gross profit	1,487.5	1,275.3	2,762.8	1,159.7	3,922.6	1,121.7	2,281.4	5,044.3	1,156.2	1,216.2	2,372.3	1,201.5	3,573.8	1,192.1	2,393.6	4,765.9	-22.3%	-4.6%	-14.1%	3.6%	-8.9%	6.3%	4.9%	-5.5%
in % of net sales	*59.8%*	*54.2%*	*57.1%*	*52.9%*	*55.8%*	*49.9%*	*51.4%*	*54.4%*	*53.9%*	*53.9%*	*53.9%*	*54.4%*	*54.1%*	*51.7%*	*53.0%*	*53.5%*								
SG&A	-711.3	-720.8	-1,432.2	-673.2	-2,105.4	-692.4	-1,365.7	-2,797.8	-683.3	-749.4	-1,432.7	-698.7	-2,131.5	-739.9	-1,438.7	-2,871.4	-3.9%	4.0%	0.0%	3.8%	1.2%	6.9%	5.3%	2.6%
in % of net sales	*28.6%*	*30.6%*	*29.6%*	*30.7%*	*29.9%*	*30.8%*	*30.8%*	*30.1%*	*31.9%*	*33.2%*	*32.5%*	*31.6%*	*32.2%*	*32.1%*	*31.9%*	*32.2%*								
Marketing and selling expenses	-567.5	-566.3	-1,133.8	-555.7	-1,689.5	-555.3	-1,110.9	-2,244.7	-550.6	-566.5	-1,117.1	-543.4	-1,660.5	-577.1	-1,120.5	-2,237.6	-3.0%	0.0%	-1.5%	-2.2%	-1.7%	3.9%	0.9%	-0.3%
thereof amortization of intangible assets (M&S)	-101.4	-100.4	-201.8	-98.2	-300.0	-99.5	-197.7	-399.5	-98.7	-99.4	-198.1	-92.1	-290.2	-94.7	-186.8	-385.0	-2.7%	-0.9%	-1.8%	-6.2%	-3.3%	-4.8%	-5.5%	-3.6%
Administration expenses	-105.0	-102.8	-207.7	-102.7	-310.5	-114.6	-217.4	-425.1	-111.9	-104.4	-216.3	-104.1	-320.4	-120.4	-224.5	-440.8	6.6%	1.5%	4.1%	1.3%	3.2%	5.0%	3.3%	3.7%
Impairment losses and reversals (IFRS 9)	-1.1	-1.2	-2.3	-0.1	-2.4	0.3	0.2	-2.1	-1.0	-0.1	-1.1	-6.2	-7.3	0.4	-5.8	-6.9	-4.1%	-90.3%	-50.2%	>1.000%	209.4%	54.7%	n.m.	230.5%
Other operating expenses/income	-37.8	-50.6	-88.3	-14.8	-103.1	-22.8	-37.6	-125.9	-19.7	-78.5	-98.2	-45.0	-143.2	-42.9	-87.9	-186.1	-47.7%	55.2%	11.2%	205.0%	38.9%	87.8%	133.9%	47.8%
Impairments**	0.0	-31.9	-31.9	0.0	-31.9	-1.8	-1.8	-33.7	0.0	-56.0	-56.0	0.0	-56.0	-29.8	-29.8	-85.8	-100.0%	75.5%	75.5%	>1.000%	75.5%	>1.000%	>1.000%	154.3%
Research and development costs	-103.8	-99.1	-203.0	-90.4	-293.3	-103.1	-193.4	-396.4	-95.4	-96.4	-191.8	-92.0	-283.8	-104.0	-196.0	-387.8	-8.1%	-2.7%	-5.5%	1.8%	-3.2%	0.9%	1.3%	-2.2%
in % of net sales	*4.2%*	*4.2%*	*4.2%*	*4.1%*	*4.2%*	*4.6%*	*4.4%*	*4.3%*	*4.5%*	*4.3%*	*4.4%*	*4.2%*	*4.3%*	*4.5%*	*4.3%*	*4.3%*								
thereof amortization of intangible assets (R&D)	-3.4	-2.0	-5.4	-2.1	-7.5	-2.1	-4.1	-9.5	-2.1	-2.1	-4.2	-2.1	-6.2	-2.7	-4.8	-9.0	-38.9%	4.5%	-22.8%	0.9%	-16.2%	31.6%	16.3%	-5.8%
EBIT	**672.4**	**455.3**	**1,127.7**	**396.1**	**1,523.8**	**326.2**	**722.3**	**1,850.0**	**377.4**	**370.3**	**747.8**	**410.8**	**1,158.6**	**348.2**	**759.0**	**1,506.7**	-43.9%	-18.7%	-33.7%	3.7%	-24.0%	6.7%	5.1%	-18.6%
in % of net sales	*27.0%*	*19.3%*	*23.3%*	*18.1%*	*21.7%*	*14.5%*	*16.3%*	*19.9%*	*17.6%*	*16.4%*	*17.0%*	*18.6%*	*17.5%*	*15.1%*	*16.8%*	*16.9%*								
Depreciation and amortization	211.7	243.1	454.8	204.6	659.4	222.0	426.6	881.4	207.4	268.5	475.9	209.7	685.6	262.8	472.5	948.4	-2.0%	10.4%	4.6%	2.5%	4.0%	18.4%	10.8%	7.6%
EBITDA	**884.0**	**698.5**	**1,582.5**	**600.7**	**2,183.3**	**548.2**	**1,148.9**	**2,731.4**	**584.8**	**638.8**	**1,223.7**	**620.5**	**1,844.2**	**610.9**	**1,231.5**	**2,455.1**	-33.8%	-8.5%	-22.7%	3.3%	-15.5%	11.4%	7.2%	-10.1%
in % of net sales	*35.5%*	*29.7%*	*32.7%*	*27.4%*	*31.1%*	*24.4%*	*25.9%*	*29.4%*	*27.3%*	*28.3%*	*27.8%*	*28.1%*	*27.9%*	*26.5%*	*27.3%*	*27.5%*								
EBITDA pre	**900.6**	**711.9**	**1,612.5**	**615.1**	**2,227.6**	**592.0**	**1,207.1**	**2,819.6**	**611.2**	**654.7**	**1,265.9**	**646.4**	**1,912.4**	**676.8**	**1,323.3**	**2,589.2**	-32.1%	-8.0%	-21.5%	5.1%	-14.2%	14.3%	9.6%	-8.2%
in % of net sales	*36.2%*	*30.2%*	*33.3%*	*28.1%*	*31.7%*	*26.3%*	*27.2%*	*30.4%*	*28.5%*	*29.0%*	*28.8%*	*29.3%*	*28.9%*	*29.4%*	*29.3%*	*29.0%*								

Reconciliation to EBITDA pre

EBITDA	884.0	698.5	1,582.5	600.7	2,183.3	548.2	1,148.9	2,731.4	584.8	638.8	1,223.7	620.5	1,844.2	610.9	1,231.5	2,455.1	-33.8%	-8.5%	-22.7%	3.3%	-15.5%	11.4%	7.2%	-10.1%
Adjustments																								
thereof: Cost of Sales	0.2	-0.1	0.1	2.8	3.0	3.2	6.1	6.2	0.8	0.9	1.6	0.7	2.3	22.3	23.0	24.6	276.6%	n.m.	>1.000%	-76.8%	-22.9%	593.3%	280.1%	298.4%
thereof: Marketing and selling expenses	-1.2	0.3	-0.9	0.3	-0.6	12.9	13.2	12.3	5.3	4.0	9.3	-0.8	8.5	16.4	15.6	24.8	n.m.	>1.000%	n.m.	n.m.	n.m.	27.3%	18.3%	102.5%
thereof: Administration expenses	11.1	12.0	23.0	9.0	32.0	20.8	29.8	52.8	17.1	8.3	25.5	5.9	31.4	26.9	32.8	58.3	54.9%	-30.6%	10.5%	-34.5%	-2.2%	29.4%	10.1%	10.2%
thereof: Other operating expenses/income	6.4	0.5	6.9	2.3	9.2	4.6	6.9	13.8	2.6	2.6	5.2	20.0	25.3	0.3	20.3	25.5	-59.8%	459.3%	-24.3%	780.4%	174.7%	-94.4%	193.2%	84.4%
thereof: Research and development	0.0	0.7	0.8	0.0	0.8	2.3	2.3	3.1	0.6	0.1	0.7	0.1	0.8	0.0	0.1	0.8	>1.000%	-86.1%	-11.9%	n.m.	1.9%	-99.6%	-95.1%	-74.5%
Total	**16.5**	**13.4**	**29.9**	**14.4**	**44.4**	**43.8**	**58.2**	**88.2**	**26.4**	**15.9**	**42.2**	**25.9**	**68.2**	**65.9**	**91.8**	**134.0**	59.4%	18.6%	41.1%	79.6%	53.6%	50.4%	57.6%	52.0%
EBITDA pre	**900.6**	**711.9**	**1,612.5**	**615.1**	**2,227.6**	**592.0**	**1,207.1**	**2,819.6**	**611.2**	**654.7**	**1,265.9**	**646.4**	**1,912.4**	**676.8**	**1,323.3**	**2,589.2**	-32.1%	-8.0%	-21.5%	5.1%	-14.2%	14.3%	9.6%	-8.2%

Due to rounding the sum of individual values may not add up to totals presented.

** Only reflects impairments classified as adjustments.

Detailed reconciliation - Life Science

€ million	2023								2024								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	**672.4**	**455.3**	**1,127.7**	**396.1**	**1,523.8**	**326.2**	**722.3**	**1,850.0**	**377.4**	**370.3**	**747.8**	**410.8**	**1,158.6**	**348.2**	**759.0**	**1,506.7**	-43.9%	-18.7%	-33.7%	3.7%	-24.0%	6.7%	5.1%	-18.6%
Regular depreciation and amortization*	93.5	95.4	188.9	96.1	285.0	111.4	207.5	396.4	99.5	104.1	203.7	109.8	313.5	122.9	232.8	436.4	6.5%	9.1%	7.8%	14.3%	10.0%	10.3%	12.2%	10.1%
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.9	1.1	1.1	-100.0%	n.m.	-100.0%	n.m.	n.m.	>1.000%	>1.000%	>1.000%
Amortization of purchased intangible assets	118.2	115.8	234.0	108.5	342.5	108.8	217.3	451.3	107.8	108.4	216.3	99.7	316.0	109.2	208.9	425.1	-8.7%	-6.4%	-7.6%	-8.1%	-7.7%	0.4%	-3.9%	-5.8%
Impairments (net)**	0.0	31.9	31.9	0.0	31.9	1.8	1.8	33.7	0.0	56.0	56.0	0.0	56.0	29.8	29.8	85.8	-100.0%	75.5%	75.5%	>1.000%	75.5%	>1.000%	>1.000%	154.3%
Total depreciation and amortization	**211.7**	**243.1**	**454.8**	**204.6**	**659.4**	**222.0**	**426.6**	**881.4**	**207.4**	**268.5**	**475.9**	**209.7**	**685.6**	**262.8**	**472.5**	**948.4**	-2.0%	10.4%	4.6%	2.5%	4.0%	18.4%	10.8%	7.6%
EBITDA	**884.0**	**698.5**	**1,582.5**	**600.7**	**2,183.3**	**548.2**	**1,148.9**	**2,731.4**	**584.8**	**638.8**	**1,223.7**	**620.5**	**1,844.2**	**610.9**	**1,231.5**	**2,455.1**	-33.8%	-8.5%	-22.7%	3.3%	-15.5%	11.4%	7.2%	-10.1%
Adjustments																								
Acquisition costs	**5.0**	**-0.3**	**4.8**	**0.0**	**4.8**	**0.8**	**0.8**	**5.6**	**1.1**	**-0.4**	**0.7**	**3.5**	**4.2**	**9.3**	**12.9**	**13.5**	-78.4%	71.1%	-86.3%	n.m.	-12.9%	>1.000%	>1.000%	141.8%
Restructuring costs																								
Restructuring costs	**0.4**	**1.8**	**2.2**	**4.3**	**6.5**	**23.1**	**27.4**	**29.6**	18.0	8.6	26.6	14.3	40.9	32.4	46.7	73.4	>1.000%	365.9%	>1.000%	235.3%	528.1%	40.2%	70.6%	147.5%
Total	**0.4**	**1.8**	**2.2**	**4.3**	**6.5**	**23.1**	**27.4**	**29.6**	**18.0**	**8.6**	**26.6**	**14.3**	**40.9**	**32.4**	**46.7**	**73.4**	>1.000%	365.9%	>1.000%	235.3%	528.1%	40.2%	70.6%	147.5%
Integration costs/IT costs																								
Integration Cost	0.7	1.0	1.7	0.9	2.7	0.8	1.7	3.5	1.0	0.6	1.7	0.5	2.2	3.5	4.0	5.7	40.1%	-34.3%	-1.9%	-46.2%	-17.6%	341.4%	131.6%	65.5%
ERP/HR systems	10.3	10.9	21.2	9.2	30.4	19.1	28.3	49.5	6.2	7.1	13.3	7.2	20.6	20.1	27.4	40.7	-40.4%	-34.3%	-37.3%	-21.3%	-32.4%	5.4%	-3.2%	-17.8%
Total	**11.1**	**11.8**	**22.9**	**10.1**	**33.1**	**19.9**	**30.0**	**53.0**	**7.2**	**7.8**	**15.0**	**7.8**	**22.7**	**23.7**	**31.4**	**46.4**	-35.0%	-34.3%	-34.6%	-23.6%	-31.2%	19.0%	4.6%	-12.4%
Gain (-)/ losses (+) on the divestment of businesses																								
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.5	0.8	0.8	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.3**	**0.3**	**0.5**	**0.8**	**0.8**	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	**16.5**	**13.4**	**29.9**	**14.4**	**44.4**	**43.8**	**58.2**	**88.2**	**26.4**	**15.9**	**42.2**	**25.9**	**68.2**	**65.9**	**91.8**	**134.0**	59.4%	18.6%	41.1%	79.6%	53.6%	50.4%	57.6%	52.0%
EBITDA pre	**900.6**	**711.9**	**1,612.5**	**615.1**	**2,227.6**	**592.0**	**1,207.1**	**2,819.6**	**611.2**	**654.7**	**1,265.9**	**646.4**	**1,912.4**	**676.8**	**1,323.3**	**2,589.2**	-32.1%	-8.0%	-21.5%	5.1%	-14.2%	14.3%	9.6%	-8.2%

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Healthcare

€ million	2023								2024								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	**1,905.5**	**2,049.5**	**3,955.0**	**2,066.3**	**6,021.3**	**2,031.9**	**4,098.2**	**8,053.2**	**2,047.7**	**2,136.7**	**4,184.4**	**2,133.4**	**6,317.8**	**2,136.7**	**4,270.1**	**8,454.5**	7.5%	4.3%	5.8%	3.2%	4.9%	5.2%	4.2%	5.0%
Cost of sales	-446.6	-485.9	-932.6	-540.0	-1,472.6	-556.4	-1,096.4	-2,029.0	-543.3	-505.9	-1,049.1	-555.9	-1,605.0	-595.8	-1,151.7	-2,200.8	21.6%	4.1%	12.5%	2.9%	9.0%	7.1%	5.0%	8.5%
thereof amortization of intangible assets	-1.2	-1.2	-2.3	-1.2	-3.5	-1.1	-2.3	-4.6	-1.1	-1.1	-2.3	-1.1	-3.4	-1.1	-2.3	-4.5	-3.0%	-2.4%	-2.7%	-2.0%	-2.5%	-0.5%	-1.3%	-2.0%
Gross profit	1,458.9	1,563.6	3,022.4	1,526.2	4,548.7	1,475.5	3,001.8	6,024.2	1,504.4	1,630.9	3,135.3	1,577.5	4,712.8	1,540.9	3,118.4	6,253.7	3.1%	4.3%	3.7%	3.4%	3.6%	4.4%	3.9%	3.8%
in % of net sales	*76.6%*	*76.3%*	*76.4%*	*73.9%*	*75.5%*	*72.6%*	*73.2%*	*74.8%*	*73.5%*	*76.3%*	*74.9%*	*73.9%*	*74.6%*	*72.1%*	*73.0%*	*74.0%*								
SG&A	-543.9	-546.4	-1,090.2	-481.7	-1,571.9	-570.7	-1,052.4	-2,142.6	-488.9	-684.6	-1,173.5	-505.8	-1,679.3	-591.2	-1,097.0	-2,270.6	-10.1%	25.3%	7.6%	5.0%	6.8%	3.6%	4.2%	6.0%
in % of net sales	*28.5%*	*26.7%*	*27.6%*	*23.3%*	*26.1%*	*28.1%*	*25.7%*	*26.6%*	*23.9%*	*32.0%*	*28.0%*	*23.7%*	*26.6%*	*27.7%*	*25.7%*	*26.9%*								
Marketing and selling expenses	-380.6	-422.4	-803.0	-405.5	-1,208.5	-459.1	-864.6	-1,667.6	-398.2	-437.4	-835.6	-415.8	-1,251.4	-461.9	-877.7	-1,713.3	4.6%	3.5%	4.1%	2.6%	3.6%	0.6%	1.5%	2.7%
thereof amortization of intangible assets (M&S)	-0.3	-0.4	-0.7	-0.5	-1.2	-0.5	-0.9	-1.6	-0.4	-0.4	-0.8	-0.4	-1.2	-0.4	-0.8	-1.6	29.2%	3.2%	14.8%	-10.6%	4.8%	-11.3%	-11.0%	0.3%
Administration expenses	-75.5	-79.3	-154.8	-78.8	-233.6	-80.2	-159.0	-313.8	-75.2	-78.4	-153.6	-72.9	-226.6	-86.4	-159.3	-312.9	-0.4%	-1.1%	-0.7%	-7.5%	-3.0%	7.7%	0.2%	-0.3%
Impairment losses and reversals (IFRS 9)	-1.0	-8.4	-9.4	-28.4	-37.8	-3.0	-31.3	-40.8	1.9	1.8	3.8	4.3	8.1	-5.7	-1.4	2.4	n.m.	n.m.	n.m.	n.m.	n.m.	91.3%	-95.5%	n.m.
Other operating expenses/income	-86.8	-36.2	-123.0	30.9	-92.0	-28.4	2.5	-120.5	-17.4	-170.6	-188.0	-21.3	-209.3	-37.3	-58.7	-246.7	-79.9%	371.0%	52.9%	n.m.	127.4%	31.4%	n.m.	104.8%
Impairments**	0.6	0.0	0.6	0.0	0.6	-10.5	-10.5	-9.9	0.0	-155.3	-155.3	0.0	-155.3	-4.9	-4.9	-160.1	-100.0%	n.m.	n.m.	n.m.	n.m.	-53.5%	-53.5%	>1.000%
Research and development costs	-395.3	-401.5	-796.7	-391.3	-1,188.0	-469.0	-860.3	-1,657.0	-397.5	-445.4	-842.9	-329.9	-1,172.8	-329.7	-659.6	-1,502.5	0.6%	11.0%	5.8%	-15.7%	-1.3%	-29.7%	-23.3%	-9.3%
in % of net sales	*20.7%*	*19.6%*	*20.1%*	*18.9%*	*19.7%*	*23.1%*	*21.0%*	*20.6%*	*19.4%*	*20.8%*	*20.1%*	*15.5%*	*18.6%*	*15.4%*	*15.4%*	*17.8%*								
thereof amortization of intangible assets (R&D)	-0.1	-0.1	-0.1	-0.1	-0.2	-0.1	-0.1	-0.2	-0.1	-0.1	-0.1	-0.1	-0.2	0.0	-0.1	-0.2	0.0%	0.0%	0.0%	5.7%	1.9%	-100.0%	-47.1%	-23.6%
EBIT	**519.7**	**615.8**	**1,135.5**	**653.2**	**1,788.7**	**435.9**	**1,089.1**	**2,224.6**	**618.0**	**500.9**	**1,118.9**	**741.8**	**1,860.7**	**619.9**	**1,361.7**	**2,480.6**	18.9%	-18.7%	-1.5%	13.6%	4.0%	42.2%	25.0%	11.5%
in % of net sales	*27.3%*	*30.0%*	*28.7%*	*31.6%*	*29.7%*	*21.5%*	*26.6%*	*27.6%*	*30.2%*	*23.4%*	*26.7%*	*34.8%*	*29.5%*	*29.0%*	*31.9%*	*29.3%*								
Depreciation and amortization	72.9	76.2	149.1	70.2	219.4	100.6	170.9	320.0	88.3	248.5	336.8	87.6	424.4	115.5	203.1	539.9	21.1%	226.0%	125.9%	24.7%	93.5%	14.8%	18.9%	68.7%
EBITDA	**592.6**	**692.0**	**1,284.6**	**723.4**	**2,008.1**	**536.5**	**1,259.9**	**2,544.6**	**706.3**	**749.4**	**1,455.7**	**829.4**	**2,285.1**	**735.4**	**1,564.8**	**3,020.5**	19.2%	8.3%	13.3%	14.6%	13.8%	37.1%	24.2%	18.7%
in % of net sales	*31.1%*	*33.8%*	*32.5%*	*35.0%*	*33.3%*	*26.4%*	*30.7%*	*31.6%*	*34.5%*	*35.1%*	*34.8%*	*38.9%*	*36.2%*	*34.4%*	*36.6%*	*35.7%*								
EBITDA pre	**589.6**	**703.6**	**1,293.2**	**685.4**	**1,978.5**	**564.5**	**1,249.9**	**2,543.1**	**708.0**	**719.8**	**1,427.8**	**835.7**	**2,263.5**	**731.2**	**1,566.9**	**2,994.6**	20.1%	2.3%	10.4%	21.9%	14.4%	29.5%	25.4%	17.8%
in % of net sales	*30.9%*	*34.3%*	*32.7%*	*33.2%*	*32.9%*	*27.8%*	*30.5%*	*31.6%*	*34.6%*	*33.7%*	*34.1%*	*39.2%*	*35.8%*	*34.2%*	*36.7%*	*35.4%*								

Reconciliation to EBITDA pre																								
EBITDA	592.6	692.0	1,284.6	723.4	2,008.1	536.5	1,259.9	2,544.6	706.3	749.4	1,455.7	829.4	2,285.1	735.4	1,564.8	3,020.5	19.2%	8.3%	13.3%	14.6%	13.8%	37.1%	24.2%	18.7%
Adjustments																								
thereof: Cost of Sales	0.2	-1.7	-1.5	0.3	-1.3	-0.1	0.2	-1.3	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.1	-52.4%	-99.6%	n.m.	-97.4%	n.m.	n.m.	-70.9%	n.m.
thereof: Marketing and selling expenses	0.3	4.6	4.9	5.7	10.6	18.3	23.9	28.8	3.7	-1.9	1.7	0.1	1.9	1.4	1.6	3.3	>1.000%	n.m.	-64.5%	-97.5%	-82.2%	-92.1%	-93.4%	-88.5%
thereof: Administration expenses	4.0	3.5	7.4	5.1	12.5	7.6	12.6	20.1	1.1	2.7	3.8	3.6	7.3	4.3	7.9	11.6	-72.0%	-22.9%	-49.2%	-29.6%	-41.2%	-43.0%	-37.7%	-41.9%
thereof: Other operating expenses/income	0.3	0.3	0.6	-49.3	-48.7	-2.3	-51.5	-51.0	-8.0	-34.9	-42.9	-0.1	-43.0	-7.0	-7.1	-50.0	n.m.	n.m.	n.m.	-99.8%	-11.6%	209.8%	-86.2%	-1.8%
thereof: Research and development	-7.8	5.0	-2.8	0.2	-2.6	4.5	4.7	1.9	4.8	4.6	9.4	2.7	12.1	-3.0	-0.4	9.1	n.m.	-8.2%	n.m.	>1.000%	n.m.	n.m.	n.m.	374.9%
Total	**-3.0**	**11.6**	**8.6**	**-38.1**	**-29.5**	**28.0**	**-10.1**	**-1.5**	**1.7**	**-29.6**	**-27.9**	**6.3**	**-21.7**	**-4.2**	**2.1**	**-25.9**	n.m.	n.m.	n.m.	n.m.	-26.7%	n.m.	n.m.	>1.000%
EBITDA pre	**589.6**	**703.6**	**1,293.2**	**685.4**	**1,978.5**	**564.5**	**1,249.9**	**2,543.1**	**708.0**	**719.8**	**1,427.8**	**835.7**	**2,263.5**	**731.2**	**1,566.9**	**2,994.6**	20.1%	2.3%	10.4%	21.9%	14.4%	29.5%	25.4%	17.8%

Due to rounding the sum of individual values may not add up to totals presented.

Detailed reconciliation - Healthcare

€ million	2023 Q1	2023 Q2	2023 H1	2023 Q3	2023 9M	2023 Q4	2023 H2	2023 FY	2024 Q1	2024 Q2	2024 H1	2024 Q3	2024 9M	2024 Q4	2024 H2	2024 FY
EBIT	**519.7**	**615.8**	**1,135.5**	**653.2**	**1,788.7**	**435.9**	**1,089.1**	**2,224.6**	**618.0**	**500.9**	**1,118.9**	**741.8**	**1,860.7**	**619.9**	**1,361.7**	**2,480.6**
Regular depreciation and amortization*	71.9	70.4	142.3	68.5	210.9	76.7	145.3	287.6	77.7	81.0	158.7	77.4	236.2	88.2	165.6	324.4
Impairments not adjusted	0.0	4.2	4.2	0.0	4.2	11.8	11.8	16.0	9.0	10.6	19.6	8.5	28.2	20.9	29.4	49.1
Amortization of purchased intangible assets	1.5	1.6	3.2	1.7	4.8	1.7	3.3	6.5	1.6	1.6	3.2	1.6	4.8	1.5	3.1	6.4
Impairments (net)**	-0.6	0.0	-0.6	0.0	-0.6	10.5	10.5	9.9	0.0	155.3	155.3	0.0	155.3	4.9	4.9	160.1
Total depreciation and amortization	**72.9**	**76.2**	**149.1**	**70.2**	**219.4**	**100.6**	**170.9**	**320.0**	**88.3**	**248.5**	**336.8**	**87.6**	**424.4**	**115.5**	**203.1**	**539.9**
EBITDA	**592.6**	**692.0**	**1,284.6**	**723.4**	**2,008.1**	**536.5**	**1,259.9**	**2,544.6**	**706.3**	**749.4**	**1,455.7**	**829.4**	**2,285.1**	**735.4**	**1,564.8**	**3,020.5**
Adjustments																
Acquisition costs	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Restructuring costs																
Restructuring costs	**-7.3**	**12.0**	**4.7**	**2.6**	**7.3**	**24.2**	**26.8**	31.6	5.3	2.3	7.6	3.1	10.7	-2.6	0.5	8.1
Total	**-7.3**	**12.0**	**4.7**	**2.6**	**7.3**	**24.2**	**26.8**	**31.6**	**5.3**	**2.3**	**7.6**	**3.1**	**10.7**	**-2.6**	**0.5**	**8.1**
Integration costs/IT costs																
Integration Cost	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ERP/HR systems	4.0	3.5	7.4	5.1	12.5	7.2	12.3	19.7	1.1	2.7	3.8	3.1	6.9	4.3	7.4	11.2
Total	**4.0**	**3.5**	**7.4**	**5.1**	**12.5**	**7.2**	**12.3**	**19.7**	**1.1**	**2.7**	**3.8**	**3.1**	**6.9**	**4.3**	**7.4**	**11.2**
Gain (-)/ losses (+) on the divestment of businesses																
Sale of Kuvan and Biosimilars	0.0	-7.6	-7.6	-50.5	-58.1	-4.0	-54.5	-62.1	-4.8	-28.7	-33.4	0.0	-33.4	-6.0	-6.0	-39.4
Sale of Consumer Health	0.0	4.3	4.3	4.7	9.0	0.6	5.3	9.6	0.0	-5.9	-5.8	0.0	-5.8	0.0	0.1	-5.8
Sale of Allergopharma	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total	**0.3**	**-3.9**	**-3.6**	**-45.8**	**-49.4**	**-3.4**	**-49.2**	**-52.8**	**-4.8**	**-34.5**	**-39.3**	**0.0**	**-39.3**	**-5.9**	**-5.9**	**-45.2**
Other one-time costs																
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**
Total adjustments	**-3.0**	**11.6**	**8.6**	**-38.1**	**-29.5**	**28.0**	**-10.1**	**-1.5**	**1.7**	**-29.6**	**-27.9**	**6.3**	**-21.7**	**-4.2**	**2.1**	**-25.9**
EBITDA pre	**589.6**	**703.6**	**1,293.2**	**685.4**	**1,978.5**	**564.5**	**1,249.9**	**2,543.1**	**708.0**	**719.8**	**1,427.8**	**835.7**	**2,263.5**	**731.2**	**1,566.9**	**2,994.6**

€ million	Change YoY Q1	Change YoY Q2	Change YoY H1	Change YoY Q3	Change YoY 9M	Change YoY Q4	Change YoY H2	Change YoY FY
EBIT	18.9%	-18.7%	-1.5%	13.6%	4.0%	42.2%	25.0%	11.5%
Regular depreciation and amortization*	8.0%	15.1%	11.5%	13.0%	12.0%	15.0%	14.0%	12.8%
Impairments not adjusted	>1.000%	153.4%	367.0%	>1.000%	569.6%	77.5%	149.8%	207.0%
Amortization of purchased intangible assets	3.7%	-0.9%	1.3%	-4.1%	-0.6%	-7.1%	-5.6%	-2.2%
Impairments (net)**	-100.0%	n.m.	n.m.	n.m.	n.m.	-53.5%	-53.5%	>1.000%
Total depreciation and amortization	21.1%	226.0%	125.9%	24.7%	93.5%	14.8%	18.9%	68.7%
EBITDA	19.2%	8.3%	13.3%	14.6%	13.8%	37.1%	24.2%	18.7%
Adjustments								
Acquisition costs	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Restructuring costs								
Restructuring costs	n.m.	-81.2%	60.9%	19.5%	46.2%	n.m.	-98.1%	-74.4%
Total	n.m.	-81.2%	60.9%	19.5%	46.2%	n.m.	-98.1%	-74.4%
Integration costs/IT costs								
Integration Cost	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
ERP/HR systems	-72.0%	-23.1%	-49.1%	-38.1%	-44.7%	-40.5%	-39.5%	-43.1%
Total	-72.0%	-23.1%	-49.1%	-38.1%	-44.7%	-40.5%	-39.5%	-43.1%
Gain (-)/ losses (+) on the divestment of businesses								
Sale of Kuvan and Biosimilars	>1.000%	278.0%	339.7%	-100.0%	-42.4%	49.0%	-89.1%	-36.5%
Sale of Consumer Health	3.2%	n.m.	n.m.	-99.7%	n.m.	-92.8%	-99.0%	n.m.
Sale of Allergopharma	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Others	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	n.m.	786.9%	>1.000%	n.m.	-20.4%	72.0%	-88.0%	-14.4%
Other one-time costs								
Others	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	n.m.	n.m.	n.m.	n.m.	-26.7%	n.m.	n.m.	>1.000%
EBITDA pre	20.1%	2.3%	10.4%	21.9%	14.4%	29.5%	25.4%	17.8%

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Electronics	2023								2024								Change YoY							
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Net sales	**900.7**	**899.3**	**1,800.0**	**915.9**	**2,715.9**	**943.2**	**1,859.1**	**3,659.2**	**928.4**	**957.4**	**1,885.8**	**923.0**	**2,808.8**	**976.5**	**1,899.5**	**3,785.3**	3.1%	6.5%	4.8%	0.8%	3.4%	3.5%	2.2%	3.4%
Cost of sales	-525.8	-572.2	-1,097.9	-592.2	-1,690.1	-641.9	-1,234.1	-2,332.0	-580.1	-572.8	-1,153.0	-558.4	-1,711.4	-607.5	-1,165.9	-2,318.9	10.3%	0.1%	5.0%	-5.7%	1.3%	-5.4%	-5.5%	-0.6%
thereof amortization of intangible assets	-33.6	-31.5	-65.2	-30.9	-96.1	-30.3	-61.2	-126.4	-30.0	-25.0	-55.0	-21.9	-76.9	-18.6	-40.5	-95.5	-10.8%	-20.6%	-15.6%	-29.2%	-20.0%	-38.4%	-33.8%	-24.4%
Gross profit	374.9	327.2	702.1	323.7	1,025.8	301.3	625.0	1,327.2	348.3	384.6	732.8	364.5	1,097.4	369.0	733.6	1,466.4	-7.1%	17.5%	4.4%	12.6%	7.0%	22.5%	17.4%	10.5%
in % of net sales	*41.6%*	*36.4%*	*39.0%*	*35.3%*	*37.8%*	*31.9%*	*33.6%*	*36.3%*	*37.5%*	*40.2%*	*38.9%*	*39.5%*	*39.1%*	*37.8%*	*38.6%*	*38.7%*								
SG&A	-215.1	-142.5	-357.7	-196.7	-554.3	-227.9	-424.6	-782.2	-180.0	-202.5	-382.5	-195.3	-577.8	-231.9	-427.2	-809.7	-16.3%	42.1%	6.9%	-0.7%	4.2%	1.8%	0.6%	3.5%
in % of net sales	*23.9%*	*15.8%*	*19.9%*	*21.5%*	*20.4%*	*24.2%*	*22.8%*	*21.4%*	*19.4%*	*21.2%*	*20.3%*	*21.2%*	*20.6%*	*23.7%*	*22.5%*	*21.4%*								
Marketing and selling expenses	-158.2	-147.6	-305.8	-143.7	-449.5	-141.3	-285.0	-590.8	-137.7	-141.9	-279.6	-140.5	-420.0	-147.7	-288.1	-567.7	-12.9%	-3.9%	-8.6%	-2.3%	-6.6%	4.6%	1.1%	-3.9%
thereof amortization of intangible assets (M&S)	-49.5	-48.2	-97.6	-48.1	-145.8	-49.3	-97.4	-195.0	-45.6	-45.5	-91.1	-44.5	-135.5	-45.4	-89.9	-181.0	-7.9%	-5.6%	-6.7%	-7.6%	-7.0%	-7.8%	-7.7%	-7.2%
Administration expenses	-33.0	-35.1	-68.1	-40.0	-108.0	-39.1	-79.1	-147.1	-37.2	-35.6	-72.8	-43.4	-116.2	-49.3	-92.7	-165.5	12.8%	1.6%	7.0%	8.5%	7.5%	26.1%	17.2%	12.5%
Impairment losses and reversals (IFRS 9)	-0.1	-0.1	-0.2	0.1	-0.1	0.0	0.1	-0.1	0.1	-1.4	-1.3	0.1	-1.3	-0.7	-0.7	-2.0	n.m.	>1.000%	535.6%	-34.2%	>1.000%	>1.000%	n.m.	>1.000%
Other operating expenses/income	-23.8	40.2	16.4	-13.1	3.3	-47.5	-60.6	-44.2	-5.2	-23.6	-28.8	-11.6	-40.3	-34.2	-45.7	-74.5	-78.3%	n.m.	n.m.	-11.3%	n.m.	-28.1%	-24.5%	68.7%
Impairments**	-10.3	-5.0	-15.3	-3.7	-18.9	-23.3	-27.0	-42.3	-0.5	-10.5	-11.0	-1.7	-12.7	-16.2	-17.9	-28.9	-95.3%	111.7%	-27.9%	-53.7%	-32.9%	-30.5%	-33.7%	-31.6%
Research and development costs	-74.1	-74.5	-148.7	-74.7	-223.4	-74.0	-148.7	-297.4	-73.1	-75.2	-148.2	-73.7	-221.9	-75.0	-148.7	-296.9	-1.5%	0.9%	-0.3%	-1.5%	-0.7%	1.4%	0.0%	-0.2%
in % of net sales	*8.2%*	*8.3%*	*8.3%*	*8.2%*	*8.2%*	*7.8%*	*8.0%*	*8.1%*	*7.9%*	*7.9%*	*7.9%*	*8.0%*	*7.9%*	*7.7%*	*7.8%*	*7.8%*								
thereof amortization of intangible assets (R&D)	-1.0	-0.9	-1.9	-1.0	-3.0	-1.2	-2.3	-4.2	-1.1	-1.2	-2.3	-1.2	-3.5	-2.9	-4.1	-6.4	19.5%	21.6%	20.5%	10.2%	16.9%	137.1%	78.6%	52.0%
EBIT	**85.7**	**110.1**	**195.8**	**52.3**	**248.1**	**-0.5**	**51.7**	**247.5**	**95.2**	**106.9**	**202.1**	**95.5**	**297.6**	**62.1**	**157.6**	**359.7**	11.1%	-2.9%	3.2%	82.8%	20.0%	n.m.	204.7%	45.3%
in % of net sales	*9.5%*	*12.2%*	*10.9%*	*5.7%*	*9.1%*	*-0.1%*	*2.8%*	*6.8%*	*10.3%*	*11.2%*	*10.7%*	*10.4%*	*10.6%*	*6.4%*	*8.3%*	*9.5%*								
Depreciation and amortization	142.6	134.7	277.3	133.5	410.8	157.4	290.9	568.2	129.8	135.2	265.0	122.8	387.8	139.1	261.9	526.9	-9.0%	0.4%	-4.4%	-8.0%	-5.6%	-11.6%	-10.0%	-7.3%
EBITDA	**228.2**	**244.8**	**473.1**	**185.8**	**658.8**	**156.9**	**342.6**	**815.7**	**224.9**	**242.1**	**467.0**	**218.4**	**685.4**	**201.2**	**419.6**	**886.6**	-1.4%	-1.1%	-1.3%	17.5%	4.0%	28.3%	22.5%	8.7%
in % of net sales	*25.3%*	*27.2%*	*26.3%*	*20.3%*	*24.3%*	*16.6%*	*18.4%*	*22.3%*	*24.2%*	*25.3%*	*24.8%*	*23.7%*	*24.4%*	*20.6%*	*22.1%*	*23.4%*								
EBITDA pre	**237.3**	**261.7**	**499.1**	**207.9**	**707.0**	**206.0**	**413.9**	**913.0**	**236.6**	**255.3**	**491.9**	**235.2**	**727.1**	**242.5**	**477.7**	**969.6**	-0.3%	-2.5%	-1.4%	13.2%	2.9%	17.7%	15.4%	6.2%
in % of net sales	*26.4%*	*29.1%*	*27.7%*	*22.7%*	*26.0%*	*21.8%*	*22.3%*	*25.0%*	*25.5%*	*26.7%*	*26.1%*	*25.5%*	*25.9%*	*24.8%*	*25.2%*	*25.6%*								

Reconciliation to EBITDA pre	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBITDA	228.2	244.8	473.1	185.8	658.8	156.9	342.6	815.7	224.9	242.1	467.0	218.4	685.4	201.2	419.6	886.6	-1.4%	-1.1%	-1.3%	17.5%	4.0%	28.3%	22.5%	8.7%
Adjustments																								
thereof: Cost of Sales	2.0	5.9	8.0	7.3	15.3	21.8	29.1	37.1	3.2	4.5	7.7	1.4	9.1	7.0	8.4	16.1	58.2%	-24.8%	-3.5%	-80.9%	-40.4%	-67.9%	-71.1%	-56.6%
thereof: Marketing and selling expenses	0.0	0.5	0.5	2.0	2.5	0.8	2.8	3.3	0.1	0.3	0.4	-0.6	-0.1	2.3	1.8	2.2	>1.000%	-37.7%	-13.9%	n.m.	n.m.	198.3%	-35.5%	-32.3%
thereof: Administration expenses	2.0	3.6	5.7	7.7	13.3	15.4	23.1	28.7	4.7	1.7	6.5	11.1	17.6	15.2	26.3	32.8	135.0%	-52.8%	14.3%	45.0%	32.0%	-1.0%	14.3%	14.3%
thereof: Other operating expenses/income	5.1	6.4	11.5	4.9	16.4	11.0	16.0	27.5	3.4	6.5	9.9	5.0	14.9	16.2	21.1	31.0	-33.7%	1.9%	-14.0%	0.4%	-9.6%	46.5%	32.3%	12.9%
thereof: Research and development	-0.1	0.5	0.4	0.3	0.7	0.1	0.4	0.8	0.2	0.2	0.4	0.0	0.4	0.5	0.5	0.9	n.m.	-60.9%	-1.2%	n.m.	-45.3%	411.2%	31.3%	14.7%
Total	**9.1**	**16.9**	**26.0**	**22.1**	**48.1**	**49.2**	**71.3**	**97.3**	**11.7**	**13.2**	**24.9**	**16.9**	**41.7**	**41.3**	**58.2**	**83.0**	28.3%	-22.1%	-4.4%	-23.7%	-13.3%	-16.0%	-18.4%	-14.7%
EBITDA pre	**237.3**	**261.7**	**499.1**	**207.9**	**707.0**	**206.0**	**413.9**	**913.0**	**236.6**	**255.3**	**491.9**	**235.2**	**727.1**	**242.5**	**477.7**	**969.6**	-0.3%	-2.5%	-1.4%	13.2%	2.9%	17.7%	15.4%	6.2%

Due to rounding the sum of individual values may not add up to totals presented.

** Only reflects impairments classified as adjustments.

Detailed reconciliation - Electronics

	2023								2024								Change YoY							
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	**85.7**	**110.1**	**195.8**	**52.3**	**248.1**	**-0.5**	**51.7**	**247.5**	**95.2**	**106.9**	**202.1**	**95.5**	**297.6**	**62.1**	**157.6**	**359.7**	11.1%	-2.9%	3.2%	82.8%	20.0%	n.m.	204.7%	45.3%
Regular depreciation and amortization*	48.2	49.1	97.3	49.7	147.0	53.3	103.0	200.3	52.3	53.0	105.3	53.4	158.7	56.2	109.6	214.9	8.6%	8.0%	8.3%	7.4%	8.0%	5.4%	6.3%	7.3%
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.2	0.4	-0.2	0.0	0.2	>1.000%	n.m.	>1.000%	>1.000%	>1.000%	n.m.	n.m.	>1.000%
Amortization of purchased intangible assets	84.1	80.6	164.7	80.1	244.8	80.8	160.8	325.6	76.8	71.7	148.4	67.5	215.9	66.9	134.5	282.9	-8.7%	-11.1%	-9.9%	-15.7%	-11.8%	-17.1%	-16.4%	-13.1%
Impairments (net)**	10.3	5.0	15.3	3.7	18.9	23.3	27.0	42.3	0.5	10.5	11.0	1.7	12.7	16.2	17.9	28.9	-95.3%	111.7%	-27.9%	-53.7%	-32.9%	-30.5%	-33.7%	-31.6%
Total depreciation and amortization	**142.6**	**134.7**	**277.3**	**133.5**	**410.8**	**157.4**	**290.9**	**568.2**	**129.8**	**135.2**	**265.0**	**122.8**	**387.8**	**139.1**	**261.9**	**526.9**	-9.0%	0.4%	-4.4%	-8.0%	-5.6%	-11.6%	-10.0%	-7.3%
EBITDA	**228.2**	**244.8**	**473.1**	**185.8**	**658.8**	**156.9**	**342.6**	**815.7**	**224.9**	**242.1**	**467.0**	**218.4**	**685.4**	**201.2**	**419.6**	**886.6**	-1.4%	-1.1%	-1.3%	17.5%	4.0%	28.3%	22.5%	8.7%
Adjustments																								
Acquisition costs	**4.2**	**5.1**	**9.2**	**3.7**	**12.9**	**0.0**	**3.6**	**12.9**	**1.4**	**0.8**	**2.2**	**2.0**	**4.3**	**7.8**	**9.9**	**12.1**	-65.8%	-84.1%	-75.9%	-44.5%	-67.0%	n.m.	170.6%	-6.1%
Restructuring costs																								
Restructuring costs	2.2	6.9	9.1	9.9	18.9	41.0	50.9	60.0	4.1	4.2	8.3	7.8	16.1	5.9	13.7	22.0	88.8%	-39.4%	-8.9%	-20.7%	-15.1%	-85.6%	-73.0%	-63.3%
Total	**2.2**	**6.9**	**9.1**	**9.9**	**18.9**	**41.0**	**50.9**	**60.0**	**4.1**	**4.2**	**8.3**	**7.8**	**16.1**	**5.9**	**13.7**	**22.0**	88.8%	-39.4%	-8.9%	-20.7%	-15.1%	-85.6%	-73.0%	-63.3%
Integration costs/IT costs																								
Integration Cost	1.1	1.0	2.1	1.2	3.3	0.5	1.6	3.8	1.1	1.4	2.6	-1.5	1.0	4.5	2.9	5.5	1.2%	38.3%	18.8%	n.m.	-68.7%	852.2%	79.5%	45.1%
ERP/HR systems	1.7	3.9	5.6	7.4	13.0	7.7	15.1	20.7	5.1	5.4	10.4	8.5	19.0	7.9	16.5	26.9	203.6%	38.1%	87.8%	14.8%	46.0%	3.2%	8.9%	30.1%
Total	**2.8**	**4.9**	**7.7**	**8.6**	**16.3**	**8.2**	**16.8**	**24.5**	**6.2**	**6.8**	**13.0**	**7.0**	**20.0**	**12.4**	**19.4**	**32.4**	121.9%	38.2%	68.6%	-18.4%	22.7%	51.9%	15.8%	32.4%
Gain (-)/ losses (+) on the divestment of businesses																								
Costs related to former business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.4	0.0	1.4	15.2	15.2	16.5	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**1.4**	**1.4**	**0.0**	**1.4**	**15.2**	**15.2**	**16.5**	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Other one-time costs																								
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Total adjustments	**9.1**	**16.9**	**26.0**	**22.1**	**48.1**	**49.2**	**71.3**	**97.3**	**11.7**	**13.2**	**24.9**	**16.9**	**41.7**	**41.3**	**58.2**	**83.0**	28.3%	-22.1%	-4.4%	-23.7%	-13.3%	-16.0%	-18.4%	-14.7%
EBITDA pre	**237.3**	**261.7**	**499.1**	**207.9**	**707.0**	**206.0**	**413.9**	**913.0**	**236.6**	**255.3**	**491.9**	**235.2**	**727.1**	**242.5**	**477.7**	**969.6**	-0.3%	-2.5%	-1.4%	13.2%	2.9%	17.7%	15.4%	6.2%

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany
Corporate and Other

€ million	2023 Q1	2023 Q2	2023 H1	2023 Q3	2023 9M	2023 Q4	2023 H2	2023 FY	2024 Q1	2024 Q2	2024 H1	2024 Q3	2024 9M	2024 Q4	2024 H2	2024 FY	Change YoY Q1	Change YoY Q2	Change YoY H1	Change YoY Q3	Change YoY 9M	Change YoY Q4	Change YoY H2	Change YoY FY
Net sales	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Cost of sales	-0.9	-2.6	-3.5	1.6	-1.9	-1.4	0.3	-3.2	0.3	1.4	1.7	0.5	2.2	-3.6	-3.1	-1.4	n.m.	n.m.	n.m.	-70.4%	n.m.	163.0%	n.m.	-57.1%
thereof amortization of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Gross profit	-0.9	-2.6	-3.5	1.6	-1.9	-1.4	0.3	-3.2	0.3	1.4	1.7	0.5	2.2	-3.6	-3.1	-1.4	n.m.	n.m.	n.m.	-70.4%	n.m.	163.0%	n.m.	-57.1%
SG&A	-217.8	-183.9	-401.7	-95.4	-497.1	-118.3	-213.6	-615.3	-145.0	-156.7	-301.8	-123.4	-425.2	-183.7	-307.1	-608.9	-33.4%	-14.8%	-24.9%	29.4%	-14.5%	55.3%	43.7%	-1.1%
Marketing and selling expenses	-2.8	-3.1	-5.9	0.5	-5.4	-1.9	-1.4	-7.3	-0.5	-0.1	-0.6	-1.1	-1.8	-15.9	-17.0	-17.7	-81.0%	-96.8%	-89.2%	n.m.	-67.4%	738.9%	>1.000%	143.0%
thereof amortization of intangible assets (M&S)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2%	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%
Administration expenses	-144.4	-127.9	-272.3	-90.5	-362.8	-143.4	-233.9	-506.2	-107.4	-117.7	-225.1	-88.8	-313.8	-136.6	-225.3	-450.4	-25.6%	-8.0%	-17.3%	-1.9%	-13.5%	-4.8%	-3.7%	-11.0%
Impairment losses and reversals (IFRS 9)	0.0	0.0	0.0	0.0	0.0	-7.6	-7.6	-7.6	0.0	-0.2	-0.2	-0.4	-0.6	-1.3	-1.7	-1.9	-80.5%	n.m.	n.m.	n.m.	n.m.	-83.3%	-77.9%	-75.4%
Other operating expenses/income	-70.6	-52.9	-123.5	-5.4	-128.9	34.6	29.2	-94.3	-37.2	-38.7	-75.9	-33.1	-109.0	-29.9	-63.0	-138.9	-47.4%	-26.8%	-38.6%	508.7%	-15.5%	n.m.	n.m.	47.3%
Impairments**	0.0	0.0	0.0	-0.1	-0.1	-1.2	-1.3	-1.3	0.0	-0.5	-0.5	-0.2	-0.6	-2.0	-2.1	-2.6	n.m.	n.m.	n.m.	48.2%	503.8%	60.1%	59.2%	94.2%
Research and development costs	-24.1	-25.3	-49.4	-24.7	-74.0	-20.4	-45.1	-94.4	-14.6	-30.3	-45.0	-28.2	-73.1	-18.7	-46.9	-91.9	-39.3%	19.9%	-8.9%	14.2%	-1.2%	-8.2%	4.1%	-2.7%
thereof amortization of intangible assets (R&D)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBIT	**-242.8**	**-211.7**	**-454.5**	**-118.4**	**-572.9**	**-140.0**	**-258.5**	-713.0	**-159.3**	**-185.7**	**-345.0**	**-151.1**	**-496.1**	**-205.9**	**-357.1**	**-702.1**	-34.4%	-12.3%	-24.1%	27.6%	-13.4%	47.1%	38.2%	-1.5%
Depreciation and amortization	28.4	28.2	56.6	26.9	83.5	26.7	53.6	110.2	28.1	27.9	55.9	29.2	85.1	33.4	62.6	118.5	-1.2%	-1.1%	-1.2%	8.4%	1.9%	25.4%	16.9%	7.6%
EBITDA	**-214.4**	**-183.5**	**-397.9**	**-91.5**	**-489.4**	**-113.4**	**-204.9**	**-602.8**	**-131.3**	**-157.8**	**-289.1**	**-121.9**	**-411.0**	**-172.5**	**-294.5**	**-583.5**	-38.8%	-14.0%	-27.4%	33.3%	-16.0%	52.1%	43.7%	-3.2%
EBITDA pre	**-140.5**	**-123.9**	**-264.5**	**-62.7**	**-327.2**	**-69.5**	**-132.3**	**-396.7**	**-101.9**	**-120.8**	**-222.8**	**-99.6**	**-322.4**	**-159.4**	**-259.1**	**-481.8**	-27.5%	-2.5%	-15.8%	58.8%	-1.5%	129.3%	95.9%	21.4%

Reconciliation to EBITDA pre

€ million	2023 Q1	2023 Q2	2023 H1	2023 Q3	2023 9M	2023 Q4	2023 H2	2023 FY	2024 Q1	2024 Q2	2024 H1	2024 Q3	2024 9M	2024 Q4	2024 H2	2024 FY	Change YoY Q1	Change YoY Q2	Change YoY H1	Change YoY Q3	Change YoY 9M	Change YoY Q4	Change YoY H2	Change YoY FY
EBITDA	-214.4	-183.5	-397.9	-91.5	-489.4	-113.4	-204.9	-602.8	-131.3	-157.8	-289.1	-121.9	-411.0	-172.5	-294.5	-583.5	-38.8%	-14.0%	-27.4%	33.3%	-16.0%	52.1%	43.7%	-3.2%
Adjustments																								
thereof: Cost of Sales	0.2	0.4	0.6	0.0	0.7	-0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100.0%	-99.7%	-99.8%	-34.9%	-96.9%	######	n.m.	-96.6%
thereof: Marketing and selling expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	-0.1	0.0	0.1	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
thereof: Administration expenses	54.6	22.8	77.5	12.2	89.6	54.5	66.7	144.2	20.0	17.1	37.1	10.4	47.5	3.5	13.9	51.0	-63.4%	-25.1%	-52.1%	-14.9%	-47.0%	-93.5%	-79.2%	-64.6%
thereof: Other operating expenses/income	19.0	35.0	54.0	16.6	70.6	-10.5	6.1	60.1	9.6	19.7	29.3	11.9	41.2	9.6	21.5	50.8	-49.8%	-43.7%	-45.8%	-28.0%	-41.6%	n.m.	254.0%	-15.5%
thereof: Research and development	0.0	1.3	1.3	0.0	1.3	-0.2	-0.1	1.2	-0.2	0.0	-0.2	0.0	-0.2	0.0	0.0	-0.2	n.m.	-97.5%	n.m.	######	n.m.	######	######	n.m.
Total	73.9	59.6	133.5	28.8	162.2	43.9	72.6	206.1	29.4	37.0	66.3	22.3	88.6	13.1	35.4	101.7	-60.3%	-37.9%	-50.3%	-22.5%	-45.4%	-70.2%	-51.3%	-50.6%
EBITDA pre	**-140.5**	**-123.9**	**-264.5**	**-62.7**	**-327.2**	**-69.5**	**-132.3**	**-396.7**	**-101.9**	**-120.8**	**-222.8**	**-99.6**	**-322.4**	**-159.4**	**-259.1**	**-481.8**	-27.5%	-2.5%	-15.8%	58.8%	-1.5%	129.3%	95.9%	21.4%

Due to rounding the sum of individual values may not add up to totals presented.
** Only reflects impairments classified as adjustments.

Detailed reconciliation - Corporate and Others

€ million	2023								2024								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
EBIT	**-242.8**	**-211.7**	**-454.5**	**-118.4**	**-572.9**	**-140.0**	**-258.5**	**-713.0**	**-159.3**	**-185.7**	**-345.0**	**-151.1**	**-496.1**	**-205.9**	**-357.1**	**-702.1**	-34.4%	-12.3%	-24.1%	27.6%	-13.4%	47.1%	38.2%	-1.5%
Regular depreciation and amortization*	28.4	28.2	56.6	26.8	83.4	25.4	52.2	108.8	28.1	27.4	55.5	29.2	84.6	31.3	60.5	115.9	-1.2%	-2.9%	-2.0%	8.8%	1.4%	23.2%	15.8%	6.5%
Impairments not adjusted	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.2	-0.2	0.1	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	>1.000%	>1.000%
Amortization of purchased intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.2%	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%
Impairments (net)**	0.0	0.0	0.0	0.1	0.1	1.2	1.3	1.3	0.0	0.5	0.5	0.2	0.6	2.0	2.1	2.6	n.m.	n.m.	n.m.	48.2%	503.8%	60.1%	59.2%	94.2%
Total depreciation and amortization	**28.4**	**28.2**	**56.6**	**26.9**	**83.5**	**26.7**	**53.6**	**110.2**	**28.1**	**27.9**	**55.9**	**29.2**	**85.1**	**33.4**	**62.6**	**118.5**	-1.2%	-1.1%	-1.2%	8.4%	1.9%	25.4%	16.9%	7.6%
EBITDA	**-214.4**	**-183.5**	**-397.9**	**-91.5**	**-489.4**	**-113.4**	**-204.9**	**-602.8**	**-131.3**	**-157.8**	**-289.1**	**-121.9**	**-411.0**	**-172.5**	**-294.5**	**-583.5**	-38.8%	-14.0%	-27.4%	33.3%	-16.0%	52.1%	43.7%	-3.2%
Adjustments																								
Acquisition costs	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	**0.0**	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Restructuring costs																								
Restructuring costs	49.0	18.5	67.6	7.9	75.4	52.0	59.8	127.4	17.2	19.1	36.3	12.0	48.2	-8.1	3.8	40.1	-65.0%	2.9%	-46.4%	52.3%	-36.1%	n.m.	-93.6%	-68.5%
Total	**49.0**	**18.5**	**67.6**	**7.9**	**75.4**	**52.0**	**59.8**	**127.4**	**17.2**	**19.1**	**36.3**	**12.0**	**48.2**	**-8.1**	**3.8**	**40.1**	-65.0%	2.9%	-46.4%	52.3%	-36.1%	n.m.	-93.6%	-68.5%
IT project costs																								
Integration Cost	0.0	0.1	0.1	0.1	0.2	0.1	0.2	0.3	0.1	0.1	0.2	0.0	0.2	0.0	0.0	0.2	82.1%	41.0%	60.1%	-55.4%	21.2%	n.m.	n.m.	-38.4%
ERP/HR systems	5.6	6.8	12.4	4.9	17.3	3.6	8.5	20.9	2.7	3.9	6.6	3.7	10.4	2.1	5.8	12.5	-51.1%	-42.7%	-46.5%	-24.3%	-40.2%	-41.5%	-31.6%	-40.4%
Total	**5.6**	**6.9**	**12.5**	**5.0**	**17.5**	**3.7**	**8.7**	**21.2**	**2.8**	**4.0**	**6.8**	**3.8**	**10.6**	**2.1**	**5.8**	**12.6**	-49.9%	-42.0%	-45.6%	-24.7%	-39.6%	-44.0%	-32.9%	-40.4%
Gain (-)/ losses (+) on the divestment of businesses																								
Costs related to former business activities	0.0	21.0	21.0	-3.0	18.0	-16.6	-19.6	1.4	0.0	-18.6	-18.6	0.0	-18.6	0.0	0.0	-18.6	n.m.	n.m.	n.m.	######	n.m.	######	######	n.m.
Total	**0.0**	**21.0**	**21.0**	**-3.0**	**18.0**	**-16.6**	**-19.6**	**1.4**	**0.0**	**-18.6**	**-18.6**	**0.0**	**-18.6**	**0.0**	**0.0**	**-18.6**	n.m.	n.m.	n.m.	######	n.m.	######	######	n.m.
Other one-time costs																								
Others	19.2	13.2	32.4	18.9	51.3	4.8	23.7	56.1	9.4	32.5	41.9	6.6	48.5	19.1	25.7	67.6	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Total	**19.2**	**13.2**	**32.4**	**18.9**	**51.3**	**4.8**	**23.7**	**56.1**	**9.4**	**32.5**	**41.9**	**6.6**	**48.5**	**19.1**	**25.7**	**67.6**	-51.2%	146.4%	29.3%	-65.2%	-5.5%	296.8%	8.3%	20.4%
Total adjustments	**73.9**	**59.6**	**133.5**	**28.8**	**162.2**	**43.9**	**72.6**	**206.1**	**29.4**	**37.0**	**66.3**	**22.3**	**88.6**	**13.1**	**35.4**	**101.7**	-60.3%	-37.9%	-50.3%	-22.5%	-45.4%	-70.2%	-51.3%	-50.6%
EBITDA pre	**-140.5**	**-123.9**	**-264.5**	**-62.7**	**-327.2**	**-69.5**	**-132.3**	**-396.7**	**-101.9**	**-120.8**	**-222.8**	**-99.6**	**-322.4**	**-159.4**	**-259.1**	**-481.8**	-27.5%	-2.5%	-15.8%	58.8%	-1.5%	129.3%	95.9%	21.4%

Due to rounding the sum of individual values may not add up to totals presented.

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany
Group
€ million

	2023								2024								Change YoY							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Financial result	-22.7	-75.7	-98.4	-46.0	-144.3	19.1	-26.8	-125.2	-32.2	-7.2	-39.4	-54.1	-93.5	-15.0	-69.1	-108.5	42.1%	-90.6%	-60.0%	17.7%	-35.2%	n.m.	157.6%	-13.4%
Interest result	-27.4	-48.7	-76.1	-39.2	-115.3	15.3	-23.8	-100.0	-22.1	-7.5	-29.6	-21.8	-51.4	-8.9	-30.7	-60.3	-19.4%	-84.7%	-61.2%	-44.3%	-55.4%	n.m.	29.0%	-39.7%
Interest income	20.6	36.7	57.3	25.0	82.2	70.8	95.8	153.0	28.1	45.3	73.4	37.2	110.6	53.6	90.8	164.2	36.4%	23.6%	28.2%	49.1%	34.5%	-24.3%	-5.2%	7.3%
Interest expenses	-48.0	-85.4	-133.4	-64.1	-197.5	-55.4	-119.6	-253.0	-50.1	-52.8	-103.0	-59.1	-162.0	-62.5	-121.6	-224.5	4.5%	-38.2%	-22.8%	-7.9%	-18.0%	12.8%	1.6%	-11.2%
Result from financial investments	13.4	7.4	20.8	12.7	33.5	10.6	23.2	44.1	7.3	11.1	18.3	-19.0	-0.7	2.6	-16.4	1.9	-46.0%	50.3%	-11.9%	n.m.	n.m.	-75.2%	n.m.	-95.6%
Currency difference - financing	-1.4	-4.8	-6.3	5.6	-0.6	-0.4	5.3	-1.0	6.4	8.0	14.3	1.5	15.8	11.8	13.3	27.6	n.m.	n.m.	n.m.	-73.1%	n.m.	n.m.	151.3%	n.m.
Interest quota - pensions and other provis	-7.3	-29.5	-36.8	-25.1	-61.9	-6.4	-31.5	-68.3	-23.8	-18.7	-42.5	-14.7	-57.2	-20.4	-35.2	-77.7	227.0%	-36.7%	15.4%	-41.3%	-7.6%	219.1%	11.7%	13.7%
Others	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-73.3%	700.0%	n.m.	n.m.	n.m.	75.6%	75.6%	75.6%

Cash Flow Statement Merck KGaA, Darmstadt, Germany

Group	2023								2024								Change YoY							
€ million	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Profit after tax	799.7	706.1	1,505.8	740.4	2,246.2	587.6	1,328.0	2,833.8	699.5	605.4	1,304.9	811.7	2,116.5	669.3	1,480.9	2,785.8	-12.5%	-14.3%	-13.3%	9.6%	-5.8%	13.9%	11.5%	-1.7%
Depreciation/amortization/impairment losses/reversals of impairment losses	455.5	482.3	937.8	435.2	1,373.0	506.7	941.9	1,879.7	453.5	680.1	1,133.6	449.3	1,582.9	550.8	1,000.1	2,133.8	-0.4%	41.0%	20.9%	3.2%	15.3%	8.7%	6.2%	13.5%
of tangible assets	216.6	216.7	433.3	224.3	657.6	259.6	483.9	917.2	231.5	286.1	517.5	242.6	760.2	306.3	549.0	1,066.5	6.9%	32.0%	19.4%	8.2%	15.6%	18.0%	13.5%	16.3%
of intangible assets	238.9	265.6	504.5	210.9	715.4	247.1	458.0	962.6	222.0	394.1	616.1	206.6	822.7	244.5	451.1	1,067.3	-7.1%	48.4%	22.1%	-2.0%	15.0%	-1.1%	-1.5%	10.9%
Changes in working capital	-223.9	-52.9	-276.8	-35.2	-312.0	171.5	136.3	-140.5	-177.4	-133.7	-311.2	-13.1	-324.2	261.6	248.5	-62.6	-20.8%	153.0%	12.4%	-62.8%	3.9%	52.6%	82.4%	-55.4%
Changes in inventories	-322.5	-106.3	-428.9	91.8	-337.0	248.3	340.2	-88.7	-40.9	1.1	-39.8	4.0	-35.9	71.6	75.6	35.7	-87.3%	n.m.	-90.7%	-95.7%	-89.4%	-71.2%	-77.8%	n.m.
Changes in trade accounts receivable	-116.5	14.7	-101.8	51.8	-50.0	41.6	93.3	-8.5	-64.0	-109.5	-173.6	78.1	-95.5	174.6	252.7	79.1	-45.0%	n.m.	70.6%	50.9%	90.9%	320.2%	170.8%	n.m.
Changes in trade accounts payable/ refund liabilities	215.1	38.8	253.9	-178.8	75.1	-118.5	-297.2	-43.4	-72.5	-25.3	-97.7	-95.1	-192.9	15.4	-79.8	-177.5	n.m.	n.m.	n.m.	-46.8%	n.m.	n.m.	-73.2%	309.3%
Changes in provisions	-8.0	53.3	45.3	30.2	75.5	112.9	143.1	188.4	40.0	-18.3	21.7	19.2	40.9	21.3	40.6	62.3	n.m.	n.m.	-52.1%	-36.3%	-45.8%	-81.1%	-71.7%	-67.0%
Changes in other assets and liabilities	-187.0	-421.0	-608.0	143.1	-464.9	-290.1	-147.1	-755.1	32.6	-264.8	-232.2	180.0	-52.3	-256.7	-76.7	-308.9	n.m.	-37.1%	-61.8%	25.8%	-88.8%	-11.5%	-47.8%	-59.1%
Neutralization of gain/loss on disposal of fixed assets and other disposals	-0.2	-145.5	-145.7	-7.0	-152.7	2.4	-4.6	-150.3	-7.9	-1.2	-9.2	0.0	-9.2	7.1	7.0	-2.1	>1.000%	-99.1%	-93.7%	-99.6%	-94.0%	192.7%	n.m.	-98.6%
Other non-cash income and expenses	16.5	0.1	16.7	-51.3	-34.6	-37.8	-89.1	-72.4	-5.0	-6.3	-11.3	11.3	0.0	-22.0	-10.7	-22.0	n.m.	n.m.	n.m.	n.m.	-99.9%	-41.8%	-88.0%	-69.6%
Operating Cash Flow	**852.7**	**622.4**	**1,475.2**	**1,255.4**	**2,730.6**	**1,053.1**	**2,308.5**	**3,783.7**	**1,035.1**	**861.2**	**1,896.3**	**1,458.3**	**3,354.6**	**1,231.5**	**2,689.8**	**4,586.1**	**21.4%**	**38.4%**	**28.6%**	**16.2%**	**22.9%**	**16.9%**	**16.5%**	**21.2%**
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**
Payments for investments in intangible assets	-79.0	-30.9	-109.9	-33.7	-143.5	-72.6	-106.3	-216.2	-248.0	-34.9	-282.9	-97.7	-380.6	-100.9	-198.6	-481.5	214.0%	12.8%	157.4%	190.5%	165.2%	38.9%	86.9%	122.7%
Payments from the disposal of intangible assets	4.4	125.8	130.2	4.9	135.0	0.8	5.6	135.8	5.9	1.9	7.8	0.9	8.7	9.0	9.8	17.6	35.4%	-98.5%	-94.0%	-82.0%	-93.6%	>1.000%	74.8%	-87.0%
Payments for investments in property, plant and equipment	-572.3	-295.6	-867.9	-428.4	-1,296.3	-511.0	-939.4	-1,807.4	-522.8	-315.7	-838.5	-455.7	-1,294.2	-407.4	-863.1	-1,701.6	-8.6%	6.8%	-3.4%	6.4%	-0.2%	-20.3%	-8.1%	-5.8%
Payments from the disposal of property, plant and equipment	10.1	3.3	13.4	4.2	17.6	1.1	5.4	18.7	10.7	6.0	16.7	18.1	34.8	-8.2	10.0	26.6	5.8%	83.0%	24.6%	327.8%	97.5%	n.m.	85.6%	42.0%
Payments for acquisitions less acquired cash and cash equivalents (net)	0.1	0.1	0.1	-9.4	-9.3	-2.5	-11.9	-11.8	0.0	0.0	0.0	-553.9	-553.9	-219.9	-773.8	-773.8	-100.0%	-100.0%	-100.0%	>1.000%	>1.000%	>1.000%	>1.000%	>1.000%
Payments from divestments	-0.1	-0.2	-0.2	0.0	-0.2	0.0	0.0	-0.2	6.3	0.1	6.3	0.0	6.3	0.5	0.5	6.8	n.m.	n.m.	n.m.	>1.000%	n.m.	>1.000%	>1.000%	n.m.
Payments for investments in other assets[1]	-918.9	-1,119.3	-2,038.2	-358.8	-2,397.0	-634.4	-993.2	-3,031.4	-287.5	-42.3	-329.8	-1,503.9	-1,833.7	-417.3	-1,921.2	-2,251.0	-68.7%	-96.2%	-83.8%	319.1%	-23.5%	-34.2%	93.4%	-25.7%
Payments from the disposal of other assets[2]	324.5	1,457.0	1,781.6	470.8	2,252.4	768.2	1,239.1	3,020.6	346.7	354.5	701.1	894.0	1,595.2	511.9	1,405.9	2,107.0	6.8%	-75.7%	-60.6%	89.9%	-29.2%	-33.4%	13.5%	-30.2%
Investing Cash Flow	**-1,231.1**	**140.2**	**-1,091.0**	**-350.3**	**-1,441.3**	**-450.5**	**-800.8**	**-1,891.8**	**-688.7**	**-30.5**	**-719.2**	**-1,698.2**	**-2,417.4**	**-632.4**	**-2,330.6**	**-3,049.8**	**-44.1%**	**n.m.**	**-34.1%**	**384.7%**	**67.7%**	**40.4%**	**191.0%**	**61.2%**
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**
Dividend payments to Merck KGaA shareholders	0.0	-284.3	-284.3	0.0	-284.3	0.0	0.0	-284.3	0.0	-284.3	-284.3	0.0	-284.3	0.0	0.0	-284.3	n.m.	0.0%	0.0%	n.m.	0.0%	n.m.	n.m.	0.0%
Dividend payments to non-controlling interests	0.0	-10.3	-10.3	-0.3	-10.6	-1.1	-1.4	-11.7	0.0	-9.1	-9.1	0.0	-9.1	0.0	0.0	-9.1	n.m.	-11.2%	-11.2%	-100.0%	-13.9%	n.m.	n.m.	-21.7%
Profit withdrawal by E.Merck KG	-90.4	-777.6	-868.0	0.0	-868.0	0.0	0.0	-868.0	-52.3	-694.3	-746.6	0.0	-746.6	0.0	0.0	-746.6	-42.1%	-10.7%	-14.0%	n.m.	-14.0%	n.m.	n.m.	-14.0%
Changes in financial liabilities to E. Merck KG and E. Merck Beteiligungen KG	-0.8	697.8	697.1	-100.0	597.1	-320.4	-420.4	276.7	-26.9	556.4	529.5	16.8	546.3	-315.7	-298.9	230.6	>1.000%	-20.3%	-24.0%	n.m.	-8.5%	-1.5%	-28.9%	-16.7%
Other changes in net equity	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.3	-0.1	0.0	-0.1	0.0	-0.1	0.5	0.5	0.5	>1.000%	>1.000%	n.m.	n.m.	n.m.	197.6%	96.2%	70.8%
Changes in current and non-current financial liabilities	215.6	-206.0	9.7	-202.2	-192.5	-652.7	-854.9	-845.3	-27.6	71.5	43.9	710.6	754.5	-930.6	-220.0	-176.2	n.m.	n.m.	354.4%	n.m.	n.m.	42.6%	-74.3%	-79.2%
Other changes from financing activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.1	n.m.	n.m.	n.m.	n.m.	40.6%	n.m.	n.m.	523.8%
Financing Cash Flow	**124.5**	**-580.4**	**-455.9**	**-302.4**	**-758.3**	**-974.0**	**-1,276.4**	**-1,732.3**	**-106.9**	**-359.8**	**-466.8**	**727.4**	**260.6**	**-1,245.8**	**-518.4**	**-985.2**	**n.m.**	**-38.0%**	**2.4%**	**n.m.**	**n.m.**	**27.9%**	**-59.4%**	**-43.1%**
thereof: from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**	**n.m.**
Changes in cash and cash equivalents	**-254.0**	**182.2**	**-71.7**	**602.7**	**530.9**	**-371.3**	**231.3**	**159.6**	**239.5**	**470.9**	**710.4**	**487.5**	**1,197.9**	**-646.8**	**-159.3**	**551.1**	**n.m.**	**158.4%**	**n.m.**	**-19.1%**	**125.6%**	**74.2%**	**n.m.**	**245.3%**
Changes in cash and cash equivalents due to currency translation	-15.7	-5.3	-21.1	1.7	-19.3	-12.1	-10.4	-31.4	-2.0	-5.4	-7.4	-11.5	-18.9	2.8	-8.8	-16.1	-87.5%	1.4%	-65.0%	n.m.	-2.3%	n.m.	-15.3%	-48.6%
Cash and cash equivalents as of January 1st	1,853.8	0.0	1,853.8	0.0	1,853.8	0.0	0.0	1,853.8	1,982.0	0.0	1,982.0	0.0	1,982.0	0.0	0.0	1,982.0	6.9%	n.m.	6.9%	n.m.	6.9%	n.m.	n.m.	6.9%
Cash and cash equivalents	**1,584.1**	**176.9**	**1,761.0**	**604.4**	**2,365.4**	**-383.4**	**221.0**	**1,982.0**	**2,219.6**	**465.5**	**2,685.0**	**476.0**	**3,161.0**	**-644.0**	**-168.0**	**2,517.0**	**40.1%**	**163.1%**	**52.5%**	**-21.2%**	**33.6%**	**68.0%**	**n.m.**	**27.0%**
Changes in cash and cash equivalents due to change in scope of consolidation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

[1] The lines "Payments for investments in financial assets" and "Payments from disposal of non-financial assets", which were presented separately in the previous year, have been summarized to improve clarity and transparency.
[2] The lines "Proceeds from the disposal of other financial assets" and "Proceeds from the disposal of non-financial assets", which were presented separately in the previous year, have been summarized to improve clarity and transparency.
Due to rounding the sum of individual values may not add up to totals presented.

Balance Sheet Merck KGaA, Darmstadt, Germany

Group	2023				2024				Shares of Totals				Shares of Totals			
€ million	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru
Non-current assets	**35,686.3**	**35,763.3**	**36,339.9**	**36,102.3**	**36,680.9**	**36,828.4**	**36,213.3**	**38,116.1**	73.4%	73.3%	72.8%	74.4%	74.1%	73.8%	72.2%	73.9%
Goodwill	18,077.4	18,102.2	18,466.3	17,844.9	18,180.8	18,320.6	18,092.8	19,151.9	37.2%	37.1%	37.0%	36.8%	36.7%	36.7%	36.1%	37.1%
Other intangible assets	6,953.8	6,765.2	6,716.5	6,551.3	6,480.6	6,208.0	5,845.1	6,282.4	14.3%	13.9%	13.5%	13.5%	13.1%	12.4%	11.7%	12.2%
Property, plant and equipment	8,217.9	8,393.4	8,719.2	9,055.9	9,214.4	9,433.0	9,414.7	10,025.0	16.9%	17.2%	17.5%	18.7%	18.6%	18.9%	18.8%	19.4%
Investments accounted for using the equity method	2.9	2.9	3.0	2.9	2.9	2.9	2.8	3.0	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other non-current receivables	23.9	23.2	24.4	27.5	26.9	24.9	24.6	27.3	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.0%	0.1%
Other non-current financial assets	958.9	1,040.9	989.8	980.8	1,067.7	1,062.2	1,090.1	1,172.3	2.0%	2.1%	2.0%	2.0%	2.2%	2.1%	2.2%	2.3%
Other non-current non-financial assets	99.6	88.1	96.3	115.3	138.1	133.6	128.3	133.6	0.2%	0.2%	0.2%	0.2%	0.3%	0.3%	0.3%	0.3%
Non-current income tax receivables	9.3	9.2	9.3	9.2	9.1	10.3	9.0	8.6	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Deferred tax assets	1,342.5	1,338.2	1,315.1	1,514.3	1,560.4	1,632.8	1,605.8	1,312.0	2.8%	2.7%	2.6%	3.1%	3.2%	3.3%	3.2%	2.5%
Current assets	**12,950.7**	**13,018.7**	**13,566.4**	**12,393.2**	**12,823.5**	**13,046.6**	**13,928.6**	**13,450.4**	26.6%	26.7%	27.2%	25.6%	25.9%	26.2%	27.8%	26.1%
Inventories	4,889.6	4,995.8	4,971.1	4,636.9	4,716.4	4,714.4	4,404.8	4,484.2	10.1%	10.2%	10.0%	9.6%	9.5%	9.5%	8.8%	8.7%
Trade and other current receivables	4,269.8	4,209.8	4,195.1	4,003.9	4,147.1	4,263.0	3,988.0	3,946.5	8.8%	8.6%	8.4%	8.3%	8.4%	8.5%	8.0%	7.7%
Contract assets	132.6	126.5	122.1	103.7	99.1	123.2	120.0	131.5	0.3%	0.3%	0.2%	0.2%	0.2%	0.2%	0.2%	0.3%
Other current financial assets	136.8	166.3	218.3	499.1	264.1	129.7	699.2	641.6	0.3%	0.3%	0.4%	1.0%	0.5%	0.3%	1.4%	1.2%
Other current non-financial assets	1,515.8	1,250.0	1,140.2	632.5	942.4	672.5	622.0	621.2	3.1%	2.6%	2.3%	1.3%	1.9%	1.3%	1.2%	1.2%
Current income tax receivables	421.9	509.2	554.2	472.8	434.8	458.9	355.8	511.7	0.9%	1.0%	1.1%	1.0%	0.9%	0.9%	0.7%	1.0%
Cash and cash equivalents	1,584.1	1,761.0	2,365.4	1,982.0	2,219.6	2,685.0	3,161.0	2,517.0	3.3%	3.6%	4.7%	4.1%	4.5%	5.4%	6.3%	4.9%
Assets held for sale	0.0	0.0	0.0	62.3	0.0	0.0	577.9	596.7	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	1.2%	1.2%
Total assets	**48,637.0**	**48,781.9**	**49,906.2**	**48,495.4**	**49,504.4**	**49,875.0**	**50,141.9**	**51,566.6**	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total equity	**26,230.0**	**26,771.9**	**28,294.5**	**26,754.3**	**28,074.2**	**28,616.0**	**28,393.4**	**29,987.5**	53.9%	54.9%	56.7%	55.2%	56.7%	57.4%	56.6%	58.2%
Equity capital	565.2	565.2	565.2	565.2	565.2	565.2	565.2	565.2	1.2%	1.2%	1.1%	1.2%	1.1%	1.1%	1.1%	1.1%
Capital reserves	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	3,813.7	7.8%	7.8%	7.6%	7.9%	7.7%	7.6%	7.6%	7.4%
Retained earnings	19,250.0	19,760.5	20,710.7	20,228.2	21,031.1	21,378.7	22,145.5	22,085.6	39.6%	40.5%	41.5%	41.7%	42.5%	42.9%	44.2%	42.8%
Gain/losses recognized in equity	2,520.3	2,561.2	3,132.2	2,072.6	2,585.9	2,791.6	1,798.9	3,447.7	5.2%	5.3%	6.3%	4.3%	5.2%	5.6%	3.6%	6.7%
Non-controlling interest	80.7	71.3	72.7	74.53	78.2	66.8	70.1	75.3	0.2%	0.1%	0.1%	0.2%	0.2%	0.1%	0.1%	0.1%
Non-current liabilities	**12,850.8**	**13,163.9**	**12,926.3**	**13,041.7**	**11,491.1**	**11,327.6**	**11,286.0**	**10,284.9**	26.4%	27.0%	25.9%	26.9%	23.2%	22.7%	22.5%	19.9%
Non-current provisions for employee benefits	1,965.3	1,994.5	1,773.6	2,192.0	2,132.9	2,064.2	2,068.0	1,955.7	4.0%	4.1%	3.6%	4.5%	4.3%	4.1%	4.1%	3.8%
Other non-current provisions	307.0	294.1	276.0	277.4	262.7	240.3	240.1	256.8	0.6%	0.6%	0.6%	0.6%	0.5%	0.5%	0.5%	0.5%
Non-current financial debt	9,159.3	9,495.4	9,540.5	9,239.5	7,822.5	7,822.0	7,884.2	6,997.0	18.8%	19.5%	19.1%	19.1%	15.8%	15.7%	15.7%	13.6%
Other non-current financial liabilities	142.4	141.3	142.8	147.1	150.5	130.7	136.2	134.8	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Other non-current non-financial liabilities	19.3	19.0	18.2	16.5	16.3	12.1	11.2	12.5	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Non-current income tax liabilities	38.0	37.5	41.0	39.5	39.4	39.5	39.2	36.41	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Deferred tax liabilities	1,219.4	1,182.1	1,134.3	1,129.6	1,066.7	1,018.7	907.0	891.7	2.5%	2.4%	2.3%	2.3%	2.2%	2.0%	1.8%	1.7%
Current liabilities	**9,556.2**	**8,846.1**	**8,685.4**	**8,699.4**	**9,939.1**	**9,931.4**	**10,462.5**	**11,294.2**	19.6%	18.1%	17.4%	17.9%	20.1%	19.9%	20.9%	21.9%
Current provisions for employee benefits	131.6	105.9	124.4	82.9	81.3	73.0	71.2	65.6	0.3%	0.2%	0.2%	0.2%	0.2%	0.1%	0.1%	0.1%
Other current provisions	378.8	448.1	469.0	575.0	594.0	597.3	592.9	504.7	0.8%	0.9%	0.9%	1.2%	1.2%	1.2%	1.2%	1.0%
Current financial debt	1,484.9	1,690.1	1,415.7	701.5	2,130.5	2,927.5	3,508.5	3,304.0	3.1%	3.5%	2.8%	1.4%	4.3%	5.9%	7.0%	6.4%
Other current financial liabilities	1,017.3	259.1	241.8	1,005.1	994.4	276.3	199.1	1,030.4	2.1%	0.5%	0.5%	2.1%	2.0%	0.6%	0.4%	2.0%
Trade and other current payables	2,326.1	2,402.7	2,243.8	2,545.4	2,086.0	2,121.6	1,950.0	2,274.5	4.8%	4.9%	4.5%	5.2%	4.2%	4.3%	3.9%	4.4%
Refund liabilities	947.1	963.1	990.0	876.8	880.9	890.5	853.5	868.9	1.9%	2.0%	2.0%	1.8%	1.8%	1.8%	1.7%	1.7%
Current income tax liabilities	1,461.4	1,487.8	1,580.7	1,433.4	1,564.9	1,659.7	1,672.7	1,527.5	3.0%	3.0%	3.2%	3.0%	3.2%	3.3%	3.3%	3.0%
Other current non-financial liabilities	1,809.1	1,489.4	1,620.1	1,479.4	1,607.1	1,385.4	1,517.8	1,561.8	3.7%	3.1%	3.2%	3.1%	3.2%	2.8%	3.0%	3.0%
Liabilities included in disposal groups classified as held for sale	0.0	0.0	0.0	0.0	0.0	0.0	96.7	156.8	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.3%
Total liabilities and stockholders' equity	**48,637.0**	**48,781.9**	**49,906.2**	**48,495.4**	**49,504.4**	**49,875.0**	**50,141.9**	**51,566.6**	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

	2023				2024				Shares of Totals				Shares of Totals			
	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru	31.mar	30.cze	30.wrz	31. Dez	31.mar	30.cze	30.wrz	31.gru
Financial debt	10,644.2	11,185.5	10,956.2	9,941.0	9,953.0	10,749.5	11,392.7	10,301.0	21.9%	22.9%	22.0%	20.5%	20.1%	21.6%	22.7%	20.0%
Net financial debt	8,991.9	9,354.9	8,426.5	7,500.0	7,497.9	7,949.6	7,552.9	7,155.1	18.5%	19.2%	16.9%	15.5%	15.1%	15.9%	15.1%	13.9%
Additions to Property, plant and equipment (excl. Leasing)[1]	297.9	669.6	1,108.0	1,775.2	305.3	695.0	1,122.7	1,734.9	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

Due to rounding the sum of individual values may not add up to totals presented.

[1] Figures are year-to-date figures from January 1st until stated end date.